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The	  depth	  of	  our	  knowledge	  about	  the	  molecular	  genetics	  of	  glioblastoma	  (GBM)	  stands	  in	  stark	  contrast	  with	  our	  ability	  to	  treat	  it	  successfully.	  This	  work	  reports	  research	   aimed	   at	   developing	   combination	   therapies	   to	   effectively	   inhibit	   cell	  growth	  in	  GBM	  tumorspheres.	  In	  our	  first	  study,	  our	  goal	  was	  to	  identify	  syner-­‐gistic	  pairs	  of	  drugs	  across	  three	  tumorsphere	  lines	  bearing	  genomic	  alterations	  representative	  of	   the	  established	  signaling	  subclasses	  of	  GBM	  tumors	  –	  the	  NF1	  deleted	  (represented	  by	  the	  tumorsphere	  line	  TS565),	  PGDFRA	  amplified	  (repre-­‐sented	  by	  the	  tumorsphere	  line	  TS543)	  and	  EGFR	  activated	  (represented	  by	  the	  tumorsphere	  line	  TS676)	  types.	  Using	  12	  targeted	  drug	  pairs,	  we	  identified	  drug	  combinations	  whose	  effects	  were	  cell-­‐line	  specific	  and	  reduced	  cell	  viability	  com-­‐pared	   to	   the	   single	   drugs.	  We	  quantified	   synergy	  using	   two	  measures,	   the	  well	  known	  Combination	  Index,	  as	  well	  as	  a	  measure	  we	  defined	  as	  the	  Efficacy	  Index	  that	  is	  able	  to	  detect	  synergies	  in	  instances	  where	  the	  Combination	  Index	  defined	  at	   50%	   is	   unable	   to	   capture	   synergy.	   Predominant	   among	   the	   synergistic	   drug	  combinations	  we	   report	   are	   the	   combination	   of	  MEK	   and	  AKT1/2	   inhibition	   in	  the	   line	   TS543,	   that	   of	   the	   drugs	   gefitinib	   (EGFRi)	   and	   AG538	   (IGFRi)	   in	   line	  TS565	  and	  of	  gefitinib	  and	  stattic	  (STAT3i)	  in	  line	  TS676.	  	  
In	  a	  second	  study,	  we	  sought	  to	  extend	  our	  findings	  from	  combination	  therapies	  to	   a	   clinically	  distinct,	   frequently	  observed	   subset	   of	   treatment	   resistant	  EGFR-­‐driven	  GBM	  tumors.	  To	  improve	  the	  efficacy	  of	  EGFR	  inhibition,	  we	  rationally	  se-­‐lected	  drugs	  that	   that	  may	  synergize	  with	   lapatinib	  based	  on	  the	  action	  of	   their	  
	  	  
respective	   targets	   on	   key	   oncogenic	   pathways,	   and	   explored	   the	   optimal	   se-­‐quence	   and	   timing	   of	   administration.	   In	   TS676	   tumorspheres,	   which	   have	   an	  EGFR	   amplification,	   express	   the	   EGFRvIII	   mutantation	   and	   have	   low	   PTEN	   ex-­‐pression,	  the	  combination	  of	  lapatinib	  and	  obatoclax	  was	  synergistic	  when	  obato-­‐clax	   was	   applied	   before	   lapatinib.	   The	   observed	   synergy	   correlated	   positively	  with	  time	  delays	  from	  3h	  to	  24h.	  We	  then	  studied	  this	  combination	  in	  two	  other	  tumorsphere	  lines	  TS600,	  with	  an	  EGFR	  gain,	  and	  GBM39,	  which	  is	  EGFR	  ampli-­‐fied	  with	  the	  vIII	  mutation	  but	  PTEN	  intact.	  Sequential	  administration	  was	  only	  mildly	   beneficial	   in	   TS600	   and	   not	   beneficial	   in	   GBM39.	   A	   time-­‐course	   protein	  array	   experiment	   designed	   to	   illuminate	   the	   network	   aspects	   of	   the	   effects	   of	  lapatinib	  and	  obatoclax	  in	  TS676	  and	  TS600	  revealed	  that	  the	  most	  effective	  se-­‐quential	   combination	   in	   TS676	  was	   obatoclax	   preceding	   lapatinib	   by	   12h.	   This	  was	   associated	  with	   higher	   cleaved	   caspase-­‐3	   activation	   than	   the	   less	   effective	  co-­‐treatment	  with	  lapatinib	  and	  obatoclax.	  We	  applied	  network	  based	  modeling	  methodologies	  to	  help	  test	  hypotheses	  that	  may	  explain	  the	  increased	  vulnerabil-­‐ity	  of	  TS676	  to	  lapatinib	  upon	  pretreatment	  with	  obatoclax.	  	  
This	  study	  presents	  encouraging	  results	  demonstrating	  the	  role	  of	  drug	  combina-­‐tion	  timing	  and	  order	  on	  the	  observed	  effect	  and	  synergy	  of	   therapies	  aimed	  at	  treating	   EGFR	   driven	   GBM	   tumorspheres.	   We	   show	   that	   BCL2	   inhibition	   by	  obatoclax	  offers	  a	  potent	  and	  promising	  means	  of	   increasing	  cellular	  sensitivity	  to	  lapatinib.	  However,	  further	  work	  in	  other	  EGFR	  driven	  GBM	  models	  that	  have	  lost	  PTEN	  expression	  is	  a	  desirable	  next	  step	  towards	  revealing	  the	  relationship	  of	  sequential	  synergy	  to	  this	  well	  studied	  co-­‐occurrence	  of	  genetic	  alterations.	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CHAPTER	  1	  INTRODUCTION	  	  Among	   the	   most	   thoroughly	   profiled	   cancers	   to	   date,	   primary	   glioblastoma	  (GBM)	  is	  a	  tumor	  of	  the	  brain	  that	  is	  characterized	  by	  heterogeneity,	  invasiveness	  and	  a	  profound	  lack	  of	  response	  to	  targeted	  treatment.	  Studies	  that	  began	  in	  the	  early	  2000s	  by	   the	  work	  of	   groups	   including	  The	  Cancer	  Genome	  Atlas	   (TCGA)	  revealed	   the	   existence	   of	   transcriptomally	   defined	   subtypes	  within	   GBM	  desig-­‐nated	  as	  proneural,	  mesenchymal,	  neural,	  and	  classical	  [1-­‐3]	  and	  recurrent	  muta-­‐tions	  in	  the	  canonical	  signaling	  pathways	  that	  drive	  these	  tumors	  [4].	   	  The	  GBM	  research	   community	   has	  made	   useful	   predictive	   and	   therapeutic	   recommenda-­‐tions	   in	  small	  subsets	  of	  patients	  [5,	   	  6]	  and	  the	  molecular	  drivers	  of	  resistance	  are	  actively	  being	  studied	  in	  preclinical	  and	  clinical	  settings	  [7-­‐10].	  However,	  the	  majority	   of	   efforts	   to	   therapeutically	   target	   recurrent	   mutations	   in	   GBM	   have	  failed	   to	   show	   survival	   benefit	   in	   patients.	   Consequently,	   two	   broad	   questions	  pertaining	  to	  GBM	  therapy	  have	  been	  why	  drugs	  that	  target	  these	  known	  altera-­‐tions	  have	  been	  ineffective,	  and	  whether	  there	  exist	  molecular	  markers	  that	  can	  reliably	  predict	  patient	  response	  to	  treatment.	  	  Lack	  of	  treatment	  response	  in	  GBM	  is	  the	  result	  of	  many	  interacting	  phenomena,	  some	  of	  which	  we	  have	  begun	  to	  understand.	  For	  one,	  GBM’s	  location	  in	  the	  brain	  makes	   it	   challenging	   for	  any	  systemically	  administered	   therapeutic	   to	  cross	   the	  blood	   brain	   barrier	   (BBB).	   Efflux	   transporters	   located	   at	   the	   BBB	   can	   rapidly	  quench	  the	  tissue	  of	  drug,	  and	  many	  agents	  that	  enter	  clinical	  trials	  actually	  bind	  to	  these	  efflux	  transporters	  with	  high	  affinity	  [11,	  	  12].	  Consequently,	  there	  is	  of-­‐
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ten	   not	   enough	   drug	   in	   the	   tissue,	   and	   when	   there	   is,	   it	   can	   be	   shunted	   out	  	  quickly.	  	  	  In	  addition,	  the	  considerable	  inter-­‐	  and	  intratumoral	  heterogeneity	  of	  GBM	  com-­‐bined	  with	  its	  low	  incidence	  complicates	  the	  discovery	  of	  drugs	  that	  could	  benefit	  a	  large	  subset	  of	  patients	  [8,	  	  9].	  Thus,	  for	  example,	  while	  EGFR	  and	  PDGFR	  acti-­‐vation	   via	   amplification,	   and	   deletion	  mutations	   of	   NF1	   and	   CDKN2A	   are	   each	  fairly	   common	   in	  GBM,	  different	  patients,	   and	   even	  different	  portions	  of	   tumor	  within	  a	  patient	  can	  manifest	  various	  combinations	  of	   these	  alterations,	   leading	  to	  differences	  in	  treatment	  response	  within	  and	  across	  tumors	  [13].	  	  Thus	   the	   development	   of	   strategies	   that	   can	   thwart	   resistance	   amidst	   complex	  and	   heterogeneous	   signaling	   mechanisms	   is	   of	   prime	   importance.	   We	   ap-­‐proached	   this	   through	   a	   series	   of	   experiments	   aimed	   broadly	   at	   systematically	  quantifying	  the	  responses	  of	  GBM	  tumorsphere	  lines	  to	  targeted	  treatment	  com-­‐binations.	  Tumorsphere	  lines	  are	  derived	  from	  primary	  tumors	  using	  the	  neuro-­‐sphere	  method,	  detailed	  later	  on	  in	  this	  thesis.	  They	  represent	  a	  relatively	  homo-­‐geneous	   and	   treatment	   resistant	   fraction	   of	   the	   original	   tumor	   that	   retains	   the	  genetic	  mutations	  of	  the	  parent	  tumor.	  	  Our	  goals	  in	  this	  study	  were	  1) To	   identify	  synergistic	  pairs	  of	  drugs	   in	   three	   tumorsphere	   lines	  bearing	  genomic	  alterations	  representative	  of	  the	  signaling	  subclasses	  [4]	  of	  GBM	  tumors	  a. By	   determining	   the	   single	   drug	   dose	   response	   behavior	   of	   each	  drug	  in	  all	  three	  tumorsphere	  lines	  b. Evaluating	   the	   effect	   of	   combinations	   of	   equivalently	   inhibitory	  concentrations	  of	  each	  drug	  pair	  on	  the	  tumorsphere	  lines	  to	  calcu-­‐
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late	  two	  measures	  of	  synergy	  for	  each	  combination,	  defined	  later	  in	  this	  thesis	  c. Nominating	   drug	   combinations	   for	   further	   study	   when	   they	   are	  both	  efficacious	  and	  synergistic	  d. Relating	   the	   observations	   of	   combinatorial	   behavior	   made	   to	  known	   instances	   of	   drug	   interaction	   and	   prior	   biological	  knowledge	  in	  the	  realm	  of	  GBM	  and	  other	  related	  solid	  tumors	  	  Predominant	  among	  the	  synergistic	  drug	  combinations	  we	  reported	  are	  the	  com-­‐bination	  of	  MEK	  and	  AKT1/2	   inhibition	   in	  TS543,	   a	   tumorsphere	   line	   that	  har-­‐bors	   a	   PDGFRA	   amplification,	   that	   of	   gefitinib	   (EGFRi)	   and	   AG538	   (IGFRi)	   in	  TS565,	  which	  is	  NF1	  deleted	  and	  of	  gefitinib	  and	  stattic	  (STAT3i)	  in	  TS676,	  a	  line	  bearing	  amplified	  EGFR	  as	  well	  as	  the	  EGFRvIII	  mutation.	  	  	  	  Our	  second	  project	  sought	  to	  extend	  these	  results	  to	  a	  clinically	  defined	  subset	  of	  patients	  with	  GBM.	  We	  selected	  EGFR	  activated	  GBM	  as	  the	  subtype	  of	  choice	  for	  several	   reasons.	   Nearly	   50%	   of	   GBM	   tumors	   harbor	   EGFR	   amplifications,	   and	  many	  of	  these	  tumors	  also	  have	  the	  EGFRvIII	  mutation,	  which	  is	  a	  deletion	  vari-­‐ant	  of	  the	  extracellular	  domain	  of	  EGFR	  that	  is	  constitutively	  active.	  However,	  the	  majority	  of	  patients	  do	  not	  benefit	   from	  receiving	  EGFR	  inhibitors	   in	  treatment.	  Further,	   the	   uses	   of	   high	   concentrations	   of	   EGFR	   targeted	   drugs	   in	   pre-­‐clinical	  and	  in-­‐vivo	  studies	  has	  revealed	  that	  the	  EGFR	  signaling	  network	  in	  this	  subset	  of	  GBMs	  may	  be	  sensitive	  to	   inhibition	  in	  the	  presence	  of	  sufficiently	  high	  concen-­‐trations	  of	  the	  drug	  [7].	  In	  practice,	  such	  high	  concentrations	  of	  drug	  can	  be	  chal-­‐lenging	  to	  reach	  because	  of	  factors	  such	  as	  the	  BBB.	  One	  way	  to	  address	  this	  is	  by	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combining	  EGFR	  inhibitors	  with	  other	  drugs	  that	  synergistically	  enhance	  cellular	  sensitivity	  to	  EGFR	  inhibition.	  	  	  Another	  strategy	  for	  maximizing	  the	  observed	  synergy	  between	  two	  drugs	  is	  se-­‐quential	   administration	   [14-­‐16].	   Proteins	   change	   dynamically	   in	   time,	   both	   via	  post-­‐translational	  modifications	  that	  can	  confer	  them	  with	  contextual	  functionali-­‐ty,	  such	  as	  by	  the	  phosphorylation	  of	  a	  receptor	  tyrosine	  kinase	  (RTK)	  on	  ligand	  binding,	  and	  via	  their	  signaling	  interactions	  with	  other	  functional	  proteins,	  often	  in	  different	  locations	  such	  as	  the	  mitochondria	  and	  nucleus.	  Thus	  the	  phenotypic	  consequences	   of	   inhibiting	   a	   protein	   are	   likely	   dependent	   on	   the	   predominant	  state/s	  of	  that	  protein	  at	  the	  time	  the	  inhibition	  is	  applied.	  In	  our	  second	  project,	  we	  treat	  the	  effect	  of	  dynamic	  protein	  variations	  on	  combination	  effects	  as	  an	  ex-­‐plicit	   variable,	   investigating	   the	   effectiveness	   of	   combinations	   delivered	   both	  simultaneously	  and	  sequentially.	  Specifically,	  our	  goals	  here	  were	  2) To	  discover	  drugs	   that	  would	   cooperatively	   enhance	   the	   response	  of	   se-­‐lected	  EGFR	  driven	  tumorsphere	  lines	  to	  treatment	  with	  lapatinib,	  a	  dual	  inhibitor	  of	  EGFR	  and	  HER2.	  This	  involved	  a. Identifying	  optimal	  “second	  hits”	  –	  targets	  whose	   inhibition	  might	  synergize	  with	   the	   effects	   of	   an	  EGFR	   inhibitor.	   Towards	   this,	  we	  explored	   the	   response	  of	  TS676	   (EGFR++*)	   to	  a	   series	  of	  7	   single	  drug	   perturbations	   over	   time,	   using	   the	   data	   obtained	   to	   identify	  significant	  responders	  to	  treatment	  and	  time	  periods	  during	  which	  these	  responses	  were	  observed.	  b. Comparing	   the	   effects	   of	   simultaneous	   delivery	   of	   each	   combina-­‐tion	  with	  sequential	  administration	  in	  both	  orders	  and	  with	  differ-­‐ent	  time	  delays,	  the	  selection	  of	  which	  was	  informed	  by	  our	  single	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drug	  response	  data.	  This	  was	  performed	  using	  a	  resazurin	  cell	  via-­‐bility	  assay.	  c. Validating	   the	   observed	   sequence	   dependent	   synergy	   of	   lapatinib	  with	  the	  BCL2	  inhibitor	  obatoclax	  using	  two	  additional	  phenotypic	  assays	  selected	   for	   their	  ability	   to	  measure	   features	  of	  drug	  effect	  that	  could	  not	  be	  measured	  using	  the	  Resazurin	  assay.	  d. Extending	  the	  survey	  of	  this	  combination	  to	  other	  EGFR	  altered	  cell	  lines	   towards	   determining	   the	   dependence	   of	   these	   observations	  on	  (a)	  EGFR	  copy	  number	  and	  (b)	  the	  EGFRvIII	  mutation.	  	  e. Quantifying	  the	  protein	  correlates	  of	  the	  observed	  synergies	  by	  an-­‐alyzing	   the	   levels	   of	   46	   proteins	   in	   two	   EGFR	   altered	   GBM	   tu-­‐morsphere	   lines	   subjected	   to	   sequential	   and	   simultaneous	   inhibi-­‐tion	  by	  lapatinib	  and	  obatoclax.	  	  	  This	  thesis	  is	  organized	  as	  follows.	  The	  remainder	  of	  this	  chapter	  introduces	  the	  background	   relevant	   to	   our	   work,	   going	   over	   the	   biology	   of	   GBM,	   therapeutic	  strategies	   and	   relevant	   clinical	   trials,	   and	   the	   methods	   we	   use	   to	   address	   our	  goals.	   	  The	  second	  and	  third	  chapters	  detail	   the	  rationale,	  protocols	  and	  results	  that	  constitute	  the	  two	  projects	  I	  described	  above.	  Finally,	  an	  appendix	  details	  a	  method	  for	  Reverse	  Phase	  Protein	  Array	  data	  normalization	  I	  developed[17].	  	  	  
Glioblastoma	  –	  the	  disease	  and	  molecular	  profiling	  Glioblastoma	  (GBM)	  is	  the	  most	  frequent	  brain	  tumor	  and	  is	  almost	  always	  lethal.	  The	  median	  survival	  of	  patients	  with	  GBM	  is	  about	  15	  months	  [18],	  and	  disease	  progression	   is	   accompanied	   by	   cognitive	   decline,	   personality	   changes,	   and	   sei-­‐zures,	   making	   the	   short	   survival	   period	   extremely	   challenging.	   Several	   groups	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and	  consortia	  have	  dedicated	  their	  efforts	   towards	  cataloging	  the	  genetic	  varia-­‐tions	  represented	  across	  large	  groups	  of	  GBM	  tumors	  [1,	  	  19].	  We	  now	  know	  that	  GBMs	   cluster	   into	   a	   number	   of	   subtypes	   based	   on	   their	  mRNA	   expression	   pat-­‐terns	  [20],	  and	  that	  these	  subtypes	  also	  show	  other	  aberrations	  that	  correspond	  with	  the	  known	  subtypes,	  such	  as	  the	  amplification	  of	  specific	  Receptor	  Tyrosine	  Kinases	  and	  mutations	  leading	  to	  the	  expression	  of	  such	  malfunctioning	  variants	  as	  EGFRvIII,	  PDGFRΔ8-­‐9	  and	  the	  NF1	  deletion	  [21]	  [22].	  In	  this	  section,	  we	  will	  go	  over	  the	  results	  of	  these	  studies	  and	  what	  we	  have	  learned	  from	  them	  about	  the	  pathophysiology	  of	  GBM.	  We	  will	  then	  discuss	  preclinical	  studies	  and	  clinical	  tri-­‐als	  that	  have	  attempted	  to	  translate	  these	  findings	  to	  improvements	  in	  treatment.	  	  In	  2006,	  glioblastoma	  became	  the	  first	  tumor	  type	  to	  be	  studied	  exhaustively	  in	  a	  pilot	   study	  by	  The	  Cancer	  Genome	  Atlas,	   an	   initiative	   launched	  by	   the	  National	  Cancer	   Institute	   (NCI)	   and	   the	   National	   Human	   Genome	   Research	   Institute	  (NHGRI).	  The	  study	  integrated	  results	  from	  platforms	  present	  in	  18	  participating	  institutions,	  and	  included	  DNA	  sequencing,	  array	  CGH	  and	  mRNA	  expression	  data	  to	  identify	  mutations,	  copy	  number	  changes	  and	  transcript	  levels	  respectively	  [1].	  The	  focus	  in	  this	  study	  was	  to	  identify	  novel	  and	  recurrent	  genetic	  alterations	  in	  untreated	  GBM	  tumors.	  The	  principal	   findings	  of	   this	  study	  were	   the	   identifica-­‐tion	  of	  a	  small	  set	  of	  genes	  that	  showed	  recurrent	  mutations	  -­‐	  TP53	  (42%),	  PTEN	  (33%),	  NF1	  (21%),	  EGFR	  (18%),	  RB1	  (11%)	  and	  PI3K	  subunits	  (17%)	  [23].	  Fre-­‐quent	  amplifications	  of	  PDGFRA,	  EGFR	  and	  MET	  were	  also	  identified,	  and	  it	  was	  shown	  that	  they	  are	  largely	  mutually	  exclusive	  with	  one	  another.	  	  Subsequent	  work	  on	  GBM	  by	  the	  TCGA	  led	  to	  the	  identification	  of	  transcriptional-­‐ly	   defined	   subclasses	   -­‐	   the	   Proneural,	   Classical,	   Neural	   and	   Mesenchymal	   sub-­‐
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types	  	  -­‐	  based	  on	  the	  presence	  of	  signature	  genes	  within	  each	  class	  belonging	  to	  distinct	   developmental	   lineages	   of	   cells.	   While	   different	   transcriptomal	   signa-­‐tures	  have	  been	  derived	  across	  different	  studies	  depending	  on	  the	  data	  and	  tech-­‐nique	  used,	  some	  strong	  and	  consistent	  observations	  emerged	   from	  these	  stud-­‐ies.	  For	  example,	  the	  Proneural	  subclass	  was	  associated	  with	  PDGFRA	  amplifica-­‐tions	  and	  TP53	  and	  IDH1	  mutations.	  95%	  of	  the	  Classical	  samples	  showed	  EGFR	  amplifications	   and	  95%	  showed	  a	  homozygous	  deletion	  of	   the	   Ink4a/Arf	   locus.	  Similarly,	  the	  Mesenchymal	  subtype	  showed	  high	  expression	  of	  CHI3L1	  and	  MET,	  and	   a	   high	   frequency	   of	   NF1	  mutations.	   The	   differences	   between	   the	   subtypes	  also	  had	  consequences	  for	  response	  to	  standard	  treatment	  regimens.	  Aggressive	  treatment	  most	  favorably	  affected	  survival	  in	  the	  Classical	  subtype	  but	  made	  no	  difference	  to	  the	  Proneural	  subtype	  [3].	  	  Several	   questions	   arose	   naturally	   as	   a	   consequence.	   Could	   the	   differences	   be-­‐tween	  the	  subtypes	  be	  used	  to	  tailor	  therapies	  that	  targeted	  mutations	  specific	  to	  a	  subtype?	  Is	  there	  a	  single	  alteration	  or	  set	  of	  alterations	  that	  varies	  consistently	  across	  patients	   in	  a	   tumor-­‐subclass	  dependent	  manner	  –	  a	  biomarker	  or	   signa-­‐ture	  that	  can	  be	  measured	  in	  patient	  material	  to	  assist	  the	  diagnosis	  and	  subse-­‐quent	  treatment	  of	  a	  patient's	  disease	  specific	  to	  subclass?	  	  
Molecularly	  targeted	  treatment	  of	  GBM	  Partly	  because	  GBM	  was	  the	  first	  comprehensive	  project	  initiated	  by	  the	  TCGA,	  it	  is	  among	  the	  most	  thoroughly	  profiled	  cancers	  today.	  Careful	  studies	  of	  the	  re-­‐sults	  of	  the	  subtyping	  studies	  suggest	  that	  specific	  subclasses	  of	  patients	  (the	  IDH1	  mutant	  and	  H3F3A	  mutant	  K27	  subclass)	  have	  better	  survival	  and	  benefit	  less	  from	  aggressive	  chemotherapy	  [3,	  	  22].	  These	  patients	  comprise	  a	  very	  small	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fraction	  of	  patients	  with	  GBM.	  Despite	  extensive	  study,	  therapeutic	  advances	  in	  GBM	  have	  lagged	  behind	  those	  in	  other	  cancers	  such	  as	  breast,	  lung	  and	  colon	  cancer	  [24].	  What	  has	  hindered	  the	  translation	  of	  the	  findings	  from	  molecular	  studies	  into	  effective	  therapies?	  	  Two	  broad	  classes	  of	  mechanisms	  contribute	  to	  resistance	  to	  therapy.	  The	  first	  is	  signaling	  network	  robustness,	  wherein	  proteins	  and	  genes	  that	  interact	  with	  the	  mechanism	  being	  inhibited	  are	  able	  to	  adaptively	  counterbalance	  the	  effect	  of	  in-­‐hibition.	  Similar	  mechanisms	  of	  signaling	  robustness	  have	  been	  known	  to	  operate	  across	  different	  types	  of	  cancer.	  One	  type	  of	  robustness	  is	  when	  a	  target	  is	  innate-­‐ly	  resistant	  to	  treatment	  because	  of	  modifications	  such	  as	  steric	  hindrance	  to	  in-­‐hibitor	  binding	  [25],	  alteration	  of	  ATP	  affinity	  [26]	  or	  altered	  active	  site	  structure	  [27,	   	  28].	  In	  the	  context	  of	  GBM,	  such	  mechanisms	  could	  be	  involved	  in	  the	  pro-­‐cesses	  that	  maintain	  the	  activity	  of	  downstream	  markers	  of	  pathway	  activity	  even	  when	  a	  targeted	  protein	  such	  as	  EGFR	  is	  successfully	  inhibited	  [10].	  	  Alternatively,	  extrinsic	  resistance	  results	   from	  the	  recruitment	  of	  signaling	  pro-­‐teins	  removed	  from	  the	  target,	  such	  as	  by	  alternative	  RTKs	  that	  may	  be	  transcrip-­‐tionally	  activated	  upon	  targeting	  a	  mutated	  RTK	  [29]	  or	  by	  the	  relief	  of	  feedback	  inhibition	  imposed	  by	  a	  protein	  downstream	  of	  the	  targeted	  drug	  [30].	  An	  exam-­‐ple	  of	   extrinsic	   resistance	   is	   encountered	   in	  BRAF-­‐V600E	  melanoma,	  where	   tu-­‐mors	  that	  are	  initially	  exquisitely	  sensitive	  to	  MEK	  inhibition	  [31]	  eventually	  ac-­‐quire	  resistance	  by	  the	  by-­‐pass	  mediated	  activation	  of	  ERK,	  requiring	  ERK	  inhibi-­‐tors	   to	  maintain	   tumor	   suppression	   [32].	   A	   similar	  mechanism	   of	   resistance	   is	  observed	  in	  colorectal	  cancer	  bearing	  BRAF	  V600E,	  with	  the	  difference	  being	  that	  these	  tumors	  are	  intrinsically	  resistant	  to	  the	  inhibition	  of	  the	  BRAF	  mutant	  via	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rapid	  feedback	  mediated	  activation	  of	  EGFR.	  Tumors	  can	  also	  undergo	  clonal	  evo-­‐lution	  over	  the	  course	  of	  treatment	  to	  develop	  treatment	  resistant	  subclones	  with	  newly	  acquired	  driver	  mutations	  [33].	  	  The	  second	  class	  is	  comprised	  of	  pharmacological	  factors,	  such	  as	  the	  affinity	  of	  drug-­‐target	  binding	  being	  altered	  by	  mutations	  or	  the	  inability	  of	  sufficient	  drug	  to	  reach	  the	  tumor	  site	  because	  of	  the	  blood	  brain	  barrier	  [7,	  	  34].	  Table	  1	  briefly	  summarizes	  the	  results	  of	  some	  clinical	  trials	  of	  targeted	  agents	  for	  GBM.	  	  	  
Combination	  therapy	  as	  a	  strategy	  for	  overcoming	  drug	  resistance	  One	  strategy	  for	  overcoming	  resistance	  to	  various	  inhibitors	  is	  the	  use	  of	  combi-­‐nations	  of	  inhibitors	  that	  together,	  may	  lead	  to	  long-­‐term	  remission.	  Studies	  of	  multiple	  drug	  effects	  in	  vivo,	  accompanied	  by	  efforts	  to	  understand	  the	  mecha-­‐nisms	  of	  these	  drugs	  began	  in	  the	  early	  1950s.	  An	  early	  advocate	  of	  combinatorial	  regimens,	  Howard	  Skipper	  wrote	  in	  1954	  [37]:	  	  
It	  is	  apparent	  that	  rather	  detailed	  knowledge	  of	  a	  series	  of	  biochemical	  events	  (as	  
well	  as	  alternative	  pathways)	  must	  be	  at	  hand	  before	  rational	  attempts	  at	  sequen-­
tial	  blocking	  or	  concurrent	  blocking	  can	  be	  undertaken.	  Once	  adequate	  biochemical	  
knowledge	  is	  at	  hand	  the	  second	  requirement	  is	  the	  existence	  of	  proper	  antagonists.	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  Table	  1.	  Targeted	  therapy	  agents	  alone	  (adapted	  from	  Olson	  et	  al,	  2014	  [35])	  
DRUG	   TARGET	   AUTHOR	  (YEAR)	   Outcome	  Bevacizumab	   VEGFR	   Burkhardt	  (2012)	   Median	  PFS	  10mo	  Cilengitide	   α-­‐Integrin	   Gilbert	  (2012)	   Median	  PFS	  8	  weeks	  (terminat-­‐ed;	  slow	  accrual)	  Vorinostat	   HDAC	   Friday	  (2012)	   Median	  OS	  3.2mo	  TLN-­‐4601	   RAS-­‐MAPK	   Mason	  (2012)	   Median	  OS	  5mo	  Trabedersen	   TGFβ2	   Bogdahn	  (2011)	   Median	  OS	  10.9mo	  Rilotomumab	   HGF/SF	   Wen	  (2011)	   Median	  PFS	  4.1wk	  Romidepsin	   HDAC	   Iwamoto	  (2011)	   Median	  PFS	  8wk	  Aflibercept	   VEGFR	   de	  Groot	  (2011)	   Median	  PFS	  12wk	  COL-­‐3	   MMP	   Rudek	  (2011)	   No	  response	  Perillyl	  Alcohol	  	   RAS	   da	  Fonseca	  (2011)	  [36]	   Median	  OS	  5.9mo	  Erlotinib	   EGFR	   Raizer	  (2010)	   Median	  PFS	  2mo	  Pazopanib	   Multiple	  RTKs	   Iwamoto	  (2010)	   Median	  PFS	  12wk	  Cintredekin	  Besudotox	   IL13	   Kunwar	  (2010)	   Median	   survival	  36.4wk	  Bevacizumab	   VEGFR	   Chamberlain	  (2010)	   Median	   survival	  8.5mo	  Vorinostat	   HDAC	   Galanis	  (2009)	   Median	  OS	  5.7mo	  	  Among	  the	  first	  studies	  of	  its	  kind	  to	  address	  the	  complexity	  of	  biological	  net-­‐works	  and	  its	  consequences	  for	  therapy,	  this	  study	  took	  place	  decades	  before	  the	  human	  genome	  was	  sequenced.	  Sequential	  blocking	  referred	  to	  the	  inhibition	  of	  a	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series	  of	  enzymatic	  reactions	  that	  took	  place	  in	  serial	  order,	  in	  relative	  temporal	  proximity	  of	  each	  other,	  towards	  the	  activation	  or	  generation	  of	  a	  single	  product.	  On	  the	  other	  hand,	  concurrent	  blocking	  meant	  inhibiting	  two	  enzymes	  that	  acti-­‐vated	  or	  generated	  a	  product	  by	  two	  different	  pathways.	  	   	  	  	   	  	  	   	   	  
	  In	  the	  years	  since	  this	  study,	  combination	  treatments	  have	  become	  extremely	  common	  in	  cancer	  therapy	  [38-­‐41].	  We	  have	  also	  learned	  much	  about	  the	  genetic	  drivers	  of	  cancer,	  and	  understanding	  the	  functional	  consequences	  of	  various	  mu-­‐tations	  has	  allowed	  us	  to	  design	  therapies	  that	  target	  very	  specific	  alterations	  in	  cancer	  [42-­‐44].	  Yet,	  the	  benefit	  of	  combination	  chemo-­‐	  and	  targeted	  therapies	  has	  largely	  remained	  restricted	  to	  a	  few	  cancers,	  and	  the	  acquisition	  of	  resistance	  is	  routine,	  even	  when	  drug	  combinations	  are	  used.	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Reproduced exactly from H Skipper et al, Cancer Research  14(7), 1954Figure	  1.	  H.	  Skipper’s	  representation	  of	  sequential	  and	  concurrent	  path-­‐way	  blocking	  by	  drugs	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One	  promising	  approach	  for	  the	  study	  of	  disease	  networks	  is	  perturbation,	  often	  used	  in	  conjunction	  with	  data-­‐intensive	  protein,	  metabolite	  and	  genomics	  	  platforms.	  	  
Perturbation	  to	  explore	  network	  dynamics	  in	  complex	  systems	  Perturbation	  is	  an	  extremely	  powerful	  method	  for	  establishing	  relationships	  be-­‐tween	  the	  variables	  in	  a	  system	  of	  interacting	  elements.	  A	  perturbation	  applied	  to	  a	  gene	  or	  protein	  node	  in	  a	  cellular	  network	  can	  be	  used	  to	  model	  the	  effects	  of	  that	  node	  on	  its	  downstream	  effectors	  [45].	  Genetic	  perturbation	  techniques	  such	  as	  the	  knockout	  and	  knockdown	  of	  genes	  are	  frequently	  used	  in	  molecular	  biolo-­‐gy	  to	  assess	  the	  effects	  of	  individual	  genes	  on	  a	  network.	  While	  these	  methods	  are	  slow	   and	   laborious,	   more	   recent	   techniques	   such	   as	   high-­‐throughput	   siRNA	  screens	  and	  CRISPR-­‐Cas9	  have	  revolutionized	  experimental	  biology,	  enabling	  the	  rapid	  and	  quantitative	  modeling	  of	  genetic	  events	  [46].	  	  Another	  type	  of	  perturbation	  that	  can	  yield	  different	  types	  of	  information	  about	  cellular	   systems	   is	   the	  use	  of	   small	  molecules.	   Small	  molecules	  may	  be	  used	   to	  dynamically	   stimulate	  or	   inhibit	   selected	  nodes	   in	  a	  protein	  network	  and	  differ	  from	  genetic	  methods	  of	  perturbation	  in	  the	  following	  ways:	  	   1) The	  concentration	  and	  method	  of	  delivery	  (impulse	  versus	  sustained)	  may	  be	  modulated	   to	   yield	   different	   degrees	   of	   inhibition	   or	   stimulation	   of	   a	  node.	  2) Small	  molecules	  and	  antibodies	  may	  be	  engineered	   to	  bind	   to	  and	  affect	  specific	  sites	  in	  a	  protein,	  enabling	  the	  selective	  study	  of	  different	  aspects	  of	  that	  protein’s	  function.	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  The	  phenotypic	  effect	  of	  perturbants	  on	  a	  network	  may	  also	  be	  of	  clinical	  interest.	  In	  fact,	  many	  perturbation	  studies	  are	  conducted	  to	  help	  model	  and	  understand	  disease	  physiology	  [47-­‐50].	  While	  single	  drug	  perturbation	  can	  be	  a	  very	  useful	  means	  of	   studying	   individual	  nodes	   in	  a	  network	  and	   the	  degree	   to	  which	   they	  affect	   cellular	  phenotype,	  most	  networks	  have	  evolved	   redundancy	  and	   robust-­‐ness	   through	   feedback	   and	   cross-­‐talk	   that	   limit	   their	   responsiveness	   to	   single	  perturbations.	   The	   use	   of	  multiple	   perturbations	   in	   this	   context	  may	   allow	   the	  inference	  of	  complex	  interactions	  between	  the	  nodes	  in	  a	  biological	  network	  [51,	  52].	  Using	  combinations	  of	  inhibitors	  also	  increases	  the	  amount	  of	  data	  that	  biol-­‐ogists	  are	  able	  to	  train	  inference	  algorithms	  with,	  increasing	  the	  descriptive	  and	  predictive	  power	  of	  the	  resulting	  models.	  	  
Tumorspheres	  as	  a	  model	  for	  GBM	  One	  of	  the	  challenges	  of	  preclinical	  studies	  in	  GBM	  has	  been	  the	  identification	  of	  good	  models	  of	  the	  disease.	  GBM	  is	  characterized	  by	  heterogeneity	  and	  aspects	  of	  oncogenicity	  are	  maintained	  by	  interactions	  between	  cells	  bearing	  different	  mu-­‐tations	  or	  levels	  of	  expression	  of	  certain	  proteins	  [13].	  Inasmuch	  as	  the	  ability	  of	  a	  model	  to	  answer	  questions	  is	  limited	  by	  how	  closely	  it	  approximates	  the	  system	  under	  study,	  highly	   immortalized	  cell	   lines	   that	  have	  been	  established	   from	  hu-­‐man	  and	  mouse	  gliomas	  such	  as	  U-­‐87	  and	  U-­‐251	  differ	  from	  human	  GBM	  in	  the	  following	  ways:	  1) Genetic	  drift	  with	  passaging	  leads	  to	  their	  losing	  many	  of	  the	  alterations	  observed	  in	  patient	  tumors	  [53]	  2) Immortalization	  can	  lead	  to	  the	  acquisition	  of	  genetic	  changes	  not	  present	  in	  tumor	  [54,	  	  55]	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  One	   hypothesis	   explaining	   the	   presence	   and	   maintenance	   of	   heterogeneity	   in	  GBM	   is	   the	  Cancer	  Stem	  Cell	   (CSC)	  hypothesis,	   according	   to	  which	  only	  a	   small	  subpopulation	  of	   cells	   in	   a	   tumor	   retains	   the	   ability	   to	   self-­‐renew,	   differentiate	  and	  regenerate	  a	  tumor	  when	  transported	  to	  a	  favorable	  new	  environment.	  CSCs	  grow	  more	  slowly	  than	  the	  tumor	  bulk	  and	  often	  reside	  in	  the	  perivascular	  niche	  near	  the	  tumor	  periphery	  [56].	  As	  a	  result,	   they	  are	  more	  resistant	   than	  the	  tu-­‐mor	   bulk	   to	   chemotherapeutic	   agents	   that	   target	  mitotically	   active	   cells	   and	   to	  removal	  via	  surgery.	  	  CSCs	  can	  be	  isolated	  using	  a	  protocol	  known	  as	  the	  neurosphere	  method	  [57,	  	  58],	  which	  involves	  the	  repeated	  passaging	  of	  tumor	  derived	  cells	  in	  medium	  contain-­‐ing	  EGF	  and	  FGF	  but	  no	  serum,	  which	  selects	  for	  the	  undifferentiated	  component	  of	   the	  original	  population.	  CSCs	   in	  culture	  grow	  as	  spheroids	  also	  known	  as	   tu-­‐morspheres	  and	  are	  known	   to	   retain	   the	  alterations	  present	   in	   their	  parent	   tu-­‐mors	  better	  than	  adherent	  differentiated	  cell	  lines	  [59,	  	  60].	  Once	  transplanted	  in	  vivo,	   they	   give	   rise	   to	   heterogeneity	   reminiscent	   of	   the	   parent	   tumor,	   enabling	  their	  use	  in	  both	  in	  vitro	  and	  in	  vivo	  contexts.	  This	  makes	  them	  good	  models	  with	  which	  to	  study	  drug	  resistance.	  	  	  One	  disadvantage	  of	  using	  spheroid	  cell	  lines,	  like	  tumorsphere	  lines,	  is	  that	  cells	  may	   access	   different	   amounts	   of	   perturbants	   and	   nutrients	   depending	   on	   their	  depth	  within	   a	   neurosphere.	   This	   can	   introduce	   noise	   into	   the	   results	   that	   can	  make	  the	  interpretation	  of	  the	  results	  of	  subtle	  perturbations	  especially	  challeng-­‐ing.	   Pollard	   et	   al.	   devised	   a	  way	   to	   overcome	   this	   by	   growing	  GBM-­‐derived	   tu-­‐morsphere	  lines	  on	  an	  ECM-­‐associated	  substrate	  such	  as	  laminin	  [61].	  When	  the-­‐
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se	  cells	  are	  grown	   in	  serum	  free	  medium,	  over	  a	  coating	  of	   laminin,	   they	  retain	  their	   stem-­‐like	   characteristics	   and	  grow	  as	  adherent	  monolayers,	  making	  many	  experimental	  procedures	  less	  noisy	  and	  more	  convenient.	  
	  
Phenotypic	  assays	  
Resazurin	  assay	  The	  resazurin	  assay	  is	  a	  phenotypic	  assay	  used	  to	  provide	  a	  quantitative	  measure	  of	  the	  degree	  of	  aerobic	  respiration	  in	  a	  population	  of	  cells.	  This	  quantity	  may	  be	  used	  as	  a	  proxy	  for	  cell	  viability.	  It	  has	  been	  used	  to	  quantify	  bacterial	  content	  in	  foods	  and	  ecosystems	  [62,	  	  63],	  and	  is	  routinely	  used	  in	  biomedical	  research	  to	  quantify	  the	  effects	  of	  various	  environmental	  stimuli	  and	  treatments	  [64].	  Resaz-­‐urin	  is	  a	  blue,	  weakly	  fluorescent	  compound,	  which	  when	  oxidized	  by	  active	  mi-­‐tochondrial	  enzymes,	  fluoresces	  as	  the	  strongly	  red	  resosurfin.	  
We	  used	  resazurin	  to	  assess	  the	  effect	  of	  various	  drugs	  and	  drug	  combinations	  on	  cellular	  viability.	  In	  the	  most	  frequently	  used	  format,	  cells	  seeded	  in	  96-­‐well	  plates	  were	  subjected	  to	  various	  targeted	  drugs.	  Cellular	  activity	  was	  assessed	  after	  3	  days	  of	  treatment.	  Cell	  viability	  in	  response	  to	  drug	  treatment	  was	  quanti-­‐fied	  as	  cellular	  activity	  in	  the	  sample	  compared	  to	  the	  activity	  of	  the	  untreated	  control	  samples.	  For	  dose	  response	  measurements,	  a	  least-­‐squares	  fit	  of	  the	  dose	  response	  data	  to	  sigmoidal	  response	  curves	  was	  performed	  using	  GraphPad	  PRISM	  version	  6	  for	  Mac	  and	  EC-­‐50	  values	  were	  obtained	  by	  interpolating	  the	  drug	  concentration	  corresponding	  to	  50%	  viability	  compared	  to	  control.	  In	  other	  comparisons	  such	  as	  that	  of	  various	  combination	  treatments	  against	  each	  other,	  each	  condition	  was	  compared	  with	  the	  same	  untreated	  control.	  In	  all	  cases,	  the	  readings	  were	  background	  subtracted	  against	  a	  blank	  containing	  only	  growth	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medium	  and	  resazurin	  reagent.	  
Reverse	  Phase	  Protein	  Arrays	  Reverse	  phase	  protein	  arrays	  (RPPA)	  are	  a	  sensitive,	  sample-­‐sparing	  immunolog-­‐ical	   assay	   for	   the	   relative	   quantification	   of	   protein	   levels	   in	   a	   large	   number	   of	  samples.	  We	  used	  two	  types	  of	  RPPA	  technology	  for	  the	  experiments	  in	  this	  the-­‐sis.	  
The	  first	  method,	  referred	  to	  generically	  as	  protein	  lysate	  arrays,	  allows	  the	  sim-­‐ultaneous	  measurement	  of	  proteins	  in	  ~1000	  samples	  across	  nearly	  200	  antibod-­‐ies.	  The	  method	  was	  made	  available	  to	  us	  through	  a	  collaboration	  with	  the	  lab	  of	  Dr.	  Gordon	  Mills	  at	  the	  M.D.	  Anderson	  Cancer	  center.	  Proteins	  from	  lysed	  cells	  are	  spotted	  onto	  the	  surface	  of	  a	  nitrocellulose	  coated	  glass	  slide,	  which	  is	  then	  treat-­‐ed	  with	   primary	   antibody	   and	   a	   biotinylated	   secondary	   antibody.	   The	   primary	  antibody	  binds	  to	  sample	  spots	   in	  proportion	  with	  the	  amount	  of	  the	  protein	  of	  interest	  per	  spot.	  Each	  slide	  is	  washed	  gently	  with	  a	  biotinylated	  secondary	  anti-­‐body	   containing	   a	   recognition	   site	   for	   a	   Streptavadin-­‐HRP	   (horseradish	  peroxi-­‐dase)	   conjugate	   enzyme.	  This	   catalyzes	   a	   colorimetric	   reaction	  and	  generates	   a	  colored	  signal	  that	  can	  be	  converted	  to	  an	  intensity	  by	  imaging.	  	  
The	  detection	  system	  used	  ensures	  high	  sensitivity,	  and	  hence	  the	  protein	   from	  as	  few	  as	  3	  cell	  equivalents	  per	  spot	  can	  be	  detected	  by	  antibody.	  However,	   the	  dynamic	  range	  of	  the	  assay	  is	   inherently	  lower	  than	  that	  of	  methods	  like	  ELISA.	  To	  work	  around	  this	  limitation,	  each	  sample	  to	  be	  analyzed	  is	  spotted	  as	  a	  series	  of	   5	   dilutions.	   Further,	   RPPA	   technologies	   that	   utilize	   a	   colorimetric	   signal	   can	  have	  greater	  background	  than	  fluorescent	  RPPA.	  The	  quality	  of	  the	  data	  obtained	  are	  also	  limited	  by	  the	  quality	  of	  the	  image	  detection	  system	  used	  (in	  many	  cases	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a	  tabletop	  scanner)	  and	  the	  uniformity	  with	  which	  the	  liquid	  handling	  systems	  in	  use	  expose	  different	  parts	  of	   each	   slide	   to	   the	   reagents	  utilized.	  Many	  methods	  exist	   for	   normalizing	   and	   improving	   the	  quality	   of	   data	   obtained	   via	  RPPA.	  We	  developed	   one	   such	  method	   to	   reduce	   the	   spatial	   variability	   introduced	   across	  the	  samples	  printed	  on	  a	  single	  slide	  and	  reported	  this	  method	  recently.	  Details	  of	  the	  method	  along	  with	  instructions	  for	  use	  are	  provided	  as	  an	  appendix	  at	  the	  end	  of	  this	  thesis.	  	  
The	  second	  method,	  which	  is	  lower	  in	  throughput	  but	  has	  higher	  sensitivity	  and	  accuracy	  is	  called	  the	  Zeptosens	  (Bayer	  AG)	  protein	  array	  platform.	  In	  this	  meth-­‐od,	  100-­‐400pg	  of	  protein	  lysate	  is	  spotted	  onto	  the	  surface	  of	  glass	  chips	  in	  four	  dilutions.	  	  The	  method	  uses	  planar	  waveguide	  technology	  [65]	  to	  reduce	  the	  scat-­‐tering	  of	   light	   leading	   to	  reduced	  background	  signal	  and	  greater	  sensitivity.	  We	  performed	  these	  experiments	   in-­‐house,	  using	  a	  robotic	  arrayer	  and	  chip	  reader	  provided	  by	  the	  manufacturers.	  	  
RPPA	  has	  been	  successfully	  used	  in	  clinical	  diagnostics	  and	  biomarker	  identifica-­‐tion	  [66-­‐69],	  and	  in	  projects	  similar	  to	  ours,	  for	  the	  identification	  of	  accurate	  mo-­‐lecular	   drug	   targets,	   as	  well	   as	   the	   examination	   of	   protein	   network	   theoretical	  models	  [70-­‐72].	  
	  
ViCell	  assay	  
The	  ViCell	  Cell	  Viability	  analyzer	  uses	  microscopy	  to	  detect	  the	  number	  of	  cells	  in	  a	  sample,	  and	  in	  conjunction	  with	  the	  trypan	  blue	  dye,	  allows	  for	  the	  accurate	  de-­‐tection	  of	   the	  number	  of	   living	   and	  dead	   cells	   in	   a	   sample	  provided	   to	   the	  ma-­‐
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chine.	  Samples	  with	  the	  cells	  of	  interest	  are	  diluted	  in	  medium	  containing	  trypan	  blue,	  a	  dye	  that	  penetrates	  dead	  cells	  but	  is	  unable	  to	  enter	  living	  cells.	  The	  ma-­‐chine	  is	  able	  to	  analyze	  10	  samples	  at	  a	  time,	  and	  can	  count	  as	  few	  as	  2E4	  cells	  at	  a	  time,	  in	  0.5ml	  of	  medium.	  This	  makes	  it	  best	  suited	  to	  measuring	  cells	  grown	  in	  large	  flasks	  or	  petridishes,	  or	  to	  multiwell	  plates	  of	  up	  to	  24	  wells.	  
	  
Incucyte	  Cell	  Growth	  
The	  Incucyte	  ZOOM™	  live	  cell	  imager	  (Essen	  Biosciences,	  USA)	  is	  a	  robotic	  micro-­‐scope	  that	  can	  be	  housed	  within	  an	  incubator,	  enabling	  the	  continuous	  imaging	  of	  live	   cells	   grown	   in	   various	   formats	   including	   96-­‐well	   plates.	   The	  microscope	   is	  capable	  of	  capturing	  bright	  field	  as	  well	  as	  fluorescent	  images.	  In	  our	  application,	  we	  use	  bright	   field	  measurement	   to	  quantify	   the	  percentage	  of	  each	   image	  cap-­‐tured	  that	   is	  occupied	  by	  cells.	  Measuring	   the	  change	   in	   this	  quantity	  over	   time	  gives	  us	  a	  measure	  of	  the	  growth	  rate	  of	  the	  cells.	  Several	  groups	  have	  used	  this	  technology	  to	  quantify	  the	  responses	  of	  glioma	  and	  other	  cancer	  cell	  lines	  to	  per-­‐turbations	  [61,	  	  73].	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CHAPTER	  2	  CHARACTERIZING	  PHENOTYPIC	  RESPONSES	  TO	  TARGETED	  THERAPY	  IN	  GENETICALLY	  DISTINCT	  GBM	  TUMORSPHERE	  LINES	  	  
Introduction	  The	  majority	  of	  targeted	  drugs	  used	  in	  clinical	  trials	  in	  GBM	  have	  shown	  little	  to	  no	  benefit	  on	  patient	  survival.	  One	  of	  the	  main	  reasons	  for	  this	  is	  the	  considerable	  inter-­‐	   and	   intra-­‐tumoral	   heterogeneity	   characteristic	   of	   the	   disease.	   Stratified	  clinical	   trials	   in	   subsets	   of	   patients	   genetically	   determined	   to	  be	  more	   likely	   to	  respond	   to	  a	  particular	   treatment	  are	  desirable	  but	  hard	   to	   conduct	   in	  practice	  because	   of	   the	   low	   total	   incidence	   of	   GBM	   and	   hence	   of	   each	   observed	   subset	  [74].	  Additionally,	  retrospective	  analyses	  that	  attempt	  to	  correlate	  patients’	  cata-­‐logued	  alterations	  with	  their	  treatment	  response	  have	  not	  lead	  to	  consistent	  ob-­‐servations,	   indicating	   that	   there	   may	   be	   variability	   between	   patients	   carrying	  certain	   known	   driver	   mutations	   [75,	   	   76].	   In	   this	   context,	   the	   use	   of	   targeted	  combinations	   of	   drugs	   against	   representative	   GBM	   cell	   lines	   could	   be	   a	   useful	  strategy	  with	  which	  to	  identify	  effective	  treatments.	  The	  use	  of	  cell	  lines	  enables	  a	   large	  number	  of	  drug	  treatments	  to	  be	  tested	  simultaneously,	   in	  replicate,	  po-­‐tentially	  increasing	  the	  efficiency	  and	  statistical	  significance	  of	  the	  results.	  	  We	  investigated	  the	  effects	  of	  twelve	  targeted	  drugs	  and	  their	  combinations	  on	  three	  GBM	  tumorsphere	  lines	  displaying	  the	  hallmark	  alterations	  observed	  in	  each	  of	  the	  EGFR,	  PDGFR	  and	  NF1	  signaling	  subtypes	  as	  defined	  by	  Brennan,	  C.	  and	  others	  [4].	  Our	  goals	  were	  to	  identify	  drugs	  or	  drug	  combinations	  that	  would	  differentially	  inhibit	  specific	  cell	  lines,	  and	  to	  nominate	  successful	  drug	  combina-­‐
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tions	  for	  further	  study	  via	  computational	  analyses,	  to	  expedite	  the	  path	  to	  animal	  models	  and	  trials	  that	  might	  lead	  to	  their	  translation	  to	  clinical	  use.	  	  
	  
Experimental	  design	  and	  methods	  
Resazurin	  assay	  We	  used	  the	  resazurin	  assay,	  described	  in	  chapter	  1,	  to	  evaluate	  the	  response	  of	  each	  cell	  line	  to	  the	  12	  selected	  drugs	  and	  their	  combinations	  in	  a	  96-­‐well	  plate	  format.	  Cell	  seeding	  densities	  and	  the	  duration	  of	  the	  experiment	  were	  optimized	  so	  that	  the	  signal	  obtained	  would	  lie	  in	  the	  linear	  range	  of	  the	  assay	  (fig	  2,	  below)	  	  
Figure	  2.	  Linearity	  of	  resazurin	  assay	  within	  the	  range	  of	  cell	  numbers	  used	  in	  our	  drug	  treatment	  experiments	  
	  
Tumorsphere	  model	  system	  
For	  our	  experiments,	  we	  used	  three	  tumorsphere	  lines	  derived	  from	  primary	  GBMs	  obtained	  in	  surgery	  by	  Dr.	  Brennan.	  The	  tumor	  material	  obtained	  was	  sub-­‐jected	  to	  the	  progenitor	  cell	  selection	  using	  the	  methods	  previously	  described.	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Array	  comparative	  genomic	  hybridization	  of	  the	  lines	  in	  early	  passages	  was	  used	  to	  determine	  the	  status	  of	  their	  driver	  copy	  number	  alterations	  such	  as	  EGFR,	  PDGFR,	  MET	  and	  MDM2/4.	  The	  copy	  number	  profiles	  of	  the	  tumorsphere	  lines	  used	  in	  this	  project	  are	  listed	  in	  table	  3,	  along	  with	  representative	  images	  of	  the	  lines	  in	  their	  early	  passages.	  	  
Early	  passages	  of	  the	  lines	  were	  expanded	  into	  four	  passages	  without	  discarding	  any	  cells.	  The	  population	  that	  resulted	  was	  aliquoted	  into	  ~40	  stock	  vials	  each	  that	  were	  cryogenically	  preserved	  for	  use	  in	  the	  remainder	  of	  this	  work.	  Analysis	  of	  the	  cells	  grown	  from	  these	  vials	  using	  SNP	  arrays	  in	  their	  5th,	  10th	  and	  15th	  pas-­‐sages	  revealed	  that	  they	  continued	  to	  retain	  the	  driver	  alterations.	  In	  subsequent	  experiments,	  cells	  were	  only	  passaged	  10	  times	  after	  the	  thawing	  of	  a	  stock	  vial,	  after	  which	  the	  cells	  were	  discarded	  and	  a	  new	  vial	  used.	  
	  
Single	  drug	  IC-­50	  evaluation	  
We	  first	  determined	  the	  concentrations	  of	  single	  drugs	  that	  could	  inhibit	  cell	  via-­‐bility	  in	  the	  three	  cell	  lines.	  Our	  goal	  here	  was	  twofold.	  First,	  the	  nature	  of	  the	  dose	  response	  curve	  is	  instructive	  about	  the	  sensitivity	  of	  the	  cell	  line	  to	  the	  inhi-­‐bition	  of	  that	  target.	  Further,	  we	  used	  the	  single	  drug	  dose	  response	  curves	  ob-­‐tained	  to	  evaluate	  IC-­‐50	  (or	  IC-­‐X%	  values	  where	  appropriate,	  for	  example	  when	  50%	  inhibition	  was	  not	  reached)	  for	  comparison	  with	  the	  equivalent	  IC	  value	  for	  the	  combination.	  This	  enabled	  an	  evaluation	  of	  the	  synergy,	  additivity	  or	  antago-­‐nism	  of	  combinations.	  	  Methods	  for	  the	  evaluation	  of	  these	  are	  discussed	  in	  the	  
	  


















Table	  2.	  Comparison	  of	  the	  three	  glioblastoma	  derived	  tumorsphere	  lines	  use	  din	  the	  study	  of	  drug	  combination	  	  
responses.	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next	  section.	  Cells	  seeded	  in	  96-­‐well	  plates	  were	  subjected	  to	  different	  concentra-­‐tions	  of	  various	  targeted	  drugs.	  Cellular	  activity	  was	  assessed	  after	  3	  days	  of	  treatment.	  Cell	  viability	  in	  response	  to	  drug	  treatment	  was	  quantified	  as	  cellular	  activity	  in	  the	  sample	  compared	  to	  the	  activity	  of	  the	  untreated	  control	  samples.	  A	  least-­‐squares	  fit	  of	  the	  dose	  response	  data	  to	  sigmoidal	  response	  curves	  was	  performed	  using	  PRISM	  software.	  IC-­‐50	  values	  were	  obtained	  by	  interpolating	  the	  drug	  concentration	  corresponding	  to	  50%	  viability	  (w.r.t	  control).	  The	  results	  obtained	  are	  summarized	  in	  table	  2.	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Table	  3.	  Comparison	  of	  the	  effects	  of	  various	  targeted	  single	  drugs	  on	  cell	  viability	  and	  protein	  activity	  in	  three	  glioblastoma	  
tumorsphere	  lines.	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Combination	  effect	  determination	  
To	  evaluate	  the	  effects	  of	  drug	  combinations	  on	  the	  cell	  lines,	  we	  subjected	  them	  to	  combinations	  of	  equivalently	  inhibitory	  concentrations	  of	  each	  drug	  obtained	  using	  the	  single	  drug	  dose	  response	  in	  each	  cell	  line.	  In	  some	  cases	  the	  single	  drugs	  did	  not	  reach	  equivalently	  inhibitory	  concentrations	  over	  the	  range	  of	  con-­‐centrations	  applied	  –	  this	  usually	  happened	  when	  one	  drug	  was	  very	  effective	  and	  was	  able	  to	  reduce	  cellular	  activity	  to	  near	  zero	  values	  compared	  with	  the	  untreated	  controls,	  whereas	  the	  other	  drug	  tested	  was	  relatively	  ineffective.	  In	  these	  cases,	  we	  still	  tested	  these	  combinations.	  However,	  our	  selection	  of	  the	  range	  of	  concentrations	  to	  apply	  in	  these	  cases	  were	  influenced	  by	  the	  literature,	  and	  we	  selected	  eight	  1:2	  or	  1:3	  serial	  dilutions	  centered	  around	  the	  literature	  derived	  IC-­‐50	  for	  these	  drugs.	  	  
Cells	  were	  seeded	  in	  96	  well	  plates	  and	  treated	  simultaneously	  with	  8	  combina-­‐tions	  of	  the	  drugs	  in	  a	  1:1	  inhibitory	  concentration	  ratio.	  Cellular	  activity	  was	  as-­‐sessed	  3	  days	  after	  treatment	  and	  the	  data	  obtained	  were	  fitted	  to	  sigmoidal	  dose	  response	  curves	  as	  in	  the	  single	  drug	  treatments.	  
	  
Evaluation	  of	  drug	  combination	  effects	  We	  observed	  that	  when	  drugs	  are	  combined,	  observed	  non-­‐additive	  effects	  mani-­‐fest	  either	  as	  changes	  in	  the	  effective	  dose	  required	  to	  cause	  a	  particular	  fraction-­‐al	  change	  in	  cell	  viability,	  or	  as	  changes	  in	  the	  effective	  killing	  at	  particular	  doses	  applied.	  To	  identify	  cases	  of	  synergy	  and	  antagonism	  arising	  from	  both	  of	  these,	  we	  use	  two	  measures	  –	  the	  Combination	  Index	  (CI)	  [77]	  and	  the	  Efficacy	  Index	  –	  to	  quantify	  each	  drug	  combination.	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Here	  Fa,C	  indicates	  the	  fraction	  of	  cells	  affected	  by	  a	  condition	  c.	  Hence	  [A]Fa,AB=X%indicates	  the	  concentration	  of	  A	  at	  which	  X%	  of	  the	  cells	  are	  affected	  under	  condi-­‐tion	  AB,	  i.e.	  when	  the	  drugs	  are	  combined.	  Each	  term	  in	  the	  sum	  is	  hence	  a	  ratio	  of	  the	  dose	  of	  a	  drug	  required	  to	  cause	  an	  effect	  X	  when	  in	  combination	  with	  an-­‐other	  drug	  to	  the	  corresponding	  dose	  required	  when	  it	  is	  acting	  alone.	  The	  com-­‐bination	  index	  of	  an	  additive	  combination	  evaluates	  to	  1.	  Synergistic	  combina-­‐tions	  have	  CI<1	  and	  antagonistic	  combinations	  have	  CI>1.	  In	  the	  case	  where	  each	  individual	  drug	  has	  no	  effect,	  the	  denominators	  of	  the	  equation	  become	  extreme-­‐ly	  large	  and	  CI	  becomes	  0,	  its	  lower	  limit.	  The	  CI	  of	  antagonistic	  combinations	  is	  positive	  but	  theoretically	  uncapped.	  The	  CI	  evaluated	  for	  a	  particular	  drug	  com-­‐bination	  depends	  on	  the	  percentage	  X	  chosen	  at	  which	  to	  compare	  the	  effects	  of	  the	  single	  drugs	  with	  the	  combination.	  We	  follow	  convention	  and	  set	  X	  =	  50%.	  When	  we	  do	  this,	  we	  observe	  that	  in	  some	  instances,	  it	  is	  not	  possible	  to	  evaluate	  CI,	  because	  even	  though	  the	  combination	  is	  effective	  at	  inhibiting	  cells,	  neither	  individual	  drug	  reduces	  cell	  viability	  by	  50%	  or	  more.	  In	  such	  instances,	  we	  eval-­‐uate	  the	  effectiveness	  of	  a	  drug	  combination	  based	  on	  the	  change	  in	  cell	  viability	  that	  results	  from	  combining	  two	  drugs	  as	  compared	  to	  that	  caused	  by	  each	  drug	  alone.	  
We	  term	  this	  the	  efficacy	  index,	  EI,	  the	  ratio	  of	  the	  sum	  of	  the	  maximum	  observed	  fractions	  of	  cells	  affected	  by	  individual	  drugs	  to	  that	  observed	  when	  they	  are	  added	  to	  each	  other.	  
EI = Fa,A + Fa,BFa,AB
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The	  efficacy	  index	  is	  only	  meaningful	  in	  those	  cases	  where	  the	  individual	  drugs	  reduce	  cellular	  activity	  by	  50%	  or	  less.	  If	  the	  numerator	  exceeds	  1,	  then	  an	  evalu-­‐ation	  of	  the	  effect	  of	  the	  combination	  is	  impossible.	  In	  such	  cases,	  however,	  CI	  is	  sufficiently	  indicative	  of	  the	  degree	  of	  non-­‐additivity.	  Within	  the	  allowed	  ranges	  for	  Fa	  however,	  EI	  behaves	  in	  the	  same	  way	  as	  CI	  for	  synergistic	  and	  antagonistic	  combinations,	  with	  EI=1	  implying	  additivity,	  EI<1	  implying	  synergy	  and	  EI>1	  an-­‐tagonism.	  The	  results	  of	  these	  evaluations	  are	  summarized	  in	  Figure	  3.	  
	  
Results	  
Combinatorial	  therapy	  reveals	  tumorsphere-­line	  dependent	  synergies	  We	  used	  the	  Loewe	  additivity	  criteria	  discussed	  earlier	  to	  evaluate	  combination	  indices,	  defined	  at	  50%	  inhibition	  for	  all	  drug	  combinations.	  The	  combination	  in-­‐dices	  obtained	  are	  demonstrated	  in	  the	  heatmaps	  below,	  colored	  in	  a	  blue-­‐red	  scale	  mapping	  from	  synergy	  to	  antagonism.	  In	  cases	  where	  neither	  drug	  when	  	  used	  alone	  was	  able	  to	  inhibit	  cell	  viability	  by	  50%	  or	  more,	  we	  evaluated	  the	  efficacy	  synergy	  instead.	  This	  enabled	  the	  identification	  of	  synergies	  such	  as	  that	  of	  gefitinib	  and	  SRCi	  in	  TS676,	  whose	  CI	  defined	  at	  20%	  inhibition	  is	  evaluable	  but	  not	  high.	  However,	  as	  the	  combination	  has	  a	  much	  sharper	  effect	  on	  cell	  via-­‐bility	  than	  do	  either	  of	  the	  component	  drugs	  alone,	  the	  efficacy	  synergy	  evaluates	  to	  <	  1,	  revealing	  the	  synergy.	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The	  strategy	  of	  using	  an	  efficacy	  index	  in	  addition	  to	  a	  combination	  index	  evalu	  
	  ated	  at	  50%	  or	  greater	  inhibition	  is	  also	  relevant	  in	  the	  context	  of	  therapeutic	  use	  because	  some	  drug	  combinations	  can	  appear	  highly	  synergistic	  if	  their	  CI	  is	  eval-­‐uated	  at	  lower	  effect	  levels	  despite	  low	  efficacy.	  	  	   	  
Figure	  3.	  Heat	  map	  of	  combination	  and	  efficacy	  indices	  calculated	  in	  a	  12	  drug	  pair	  study	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Other	  notable	  synergies	  observed	  were	  that	  of	  	  (a)	  EGFRi	  (gefitinib)	  and	  STAT3i	  (stattic)	  in	  TS676.	  Subsequent	  studies	  have	  doc-­‐umented	  this	  synergy,	  not	  only	  in	  glioma	  [79]	  but	  also	  in	  ovarian	  and	  head	  and	  neck	  cancer	  [80,	  	  81],	  indicating	  the	  broad	  therapeutic	  potential	  of	  the	  combina-­‐tion.	  In	  cases	  such	  as	  this	  combination,	  where	  one	  of	  the	  component	  drugs	  effec-­‐tively	  reduced	  cellular	  activity	  by	  50%	  or	  greater	  (in	  this	  case,	  STAT3),	  whereas	  the	  other	  reached	  a	  steady	  state	  above	  50%,	  a	  combination	  index	  was	  evaluated	  by	  assigning	  an	  arbitrary	  extremely	  high	  value	  to	  the	  single	  drug	  IC-­‐50	  of	  this	  drug	  	  (in	  our	  case	  1E64μM).	  This	  procedure	  also	  enabled	  the	  detection	  of	  these	  synergies	  that	  might	  otherwise	  have	  remained	  undetected.	  	  















Combination of Gefitinib and 
Calbiochem SRCi in TS676 (EGFR++*)














Combination of Gefitinib with Stattic 
in TS676 (EGFR++*)
Figure	  4.	  Dose	  response	  curve	  of	  the	  combinations	  of	  gefitinib	  with	  static	  (STAT3i)	  and	  gefitinib	  with	  PP1	  (SRCi)	  in	  TS676	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prostate	  cancer	  [85],	  and	  malignant	  plural	  mesothelioma	  [86].	  This	  drug	  combi-­‐nation	  was	  not	  synergistic	  in	  either	  of	  the	  other	  two	  lines.	  	  	   	  
	  In	  fact,	  all	  three	  lines	  displayed	  relative	  insensitivity	  to	  gefitinib	  and	  the	  MEK	  in-­‐hibitor	  when	  used	  alone,	  with	  gefitinib	  displaying	  a	  biphasic	  dose	  response	  rela-­‐tionship	  and	  potentiating	  cell	  viability	  at	  low	  concentrations.	  This	  behavior	  of	  certain	  pharmacological	  agents,	  hormesis,	  is	  well	  documented	  in	  human	  cancer	  cell	  lines	  [87].	  	  	  	   	  
TS676 (EGFR++)









































The combination of  ZSTK474 with PD0325901 was synergistic in the NF1 deleted TS565 but 
additive in EGFR amplified TS676 and PDGFR amplified TS543.Figure	  5.	  Differences	  between	  the	  effects	  of	  dual	  PI3K	  and	  MEK	  inhibition	  across	  the	  three	  tumorsphere	  lines	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CHAPTER	  3	  SEQUENTIAL	  TREATMENT	  OF	  EGFR	  ACTIVATED	  	  GLIOBLASTOMA	  CELL	  LINES	  	  Introduction	  Nearly	  50%	  of	  GBMs	  have	  amplifications	  of	  the	  Epidermal	  Growth	  Factor	  Recep-­‐tor	  (EGFR)	  that	  frequently	  co-­‐occurs	  with	  mutations	  of	  EGFR	  [88,	  89].	  The	  most	  common	  of	  these	  mutations	  is	  EGFRvIII,	  a	  deletion	  mutant	  of	  exons	  2-­‐7	  in	  the	  ex-­‐tracellular	  domain	  of	   the	  protein	  [88].	  While	   the	  mutation	  renders	   the	  receptor	  incapable	  of	  binding	  to	  ligand,	  the	  variant	  displays	  low-­‐grade	  constitutive	  activi-­‐ty.	  The	  mutation	  also	  reduces	  the	  rate	  at	  which	  the	  receptor	  is	  internalized	  [90],	  increasing	   its	   surface	   signaling	   to	   downstream	   receptors.	   Consequently,	   these	  GBM	   tumors	   display	   a	   pathophysiology	   that	   is	   characterized	   by	   overactive	   and	  aberrant	  EGFR	  signaling,	  inhibiting	  which	  could	  be	  a	  potent	  therapeutic	  strategy.	  	  In	  reality,	  attempts	  to	  inhibit	  EGFR	  biochemically	  have	  shown	  little	  to	  no	  benefit	  on	  survival	  in	  clinical	  trials	  of	  GBM	  [7,	  91].	  Several	  groups	  have	  attempted	  to	  un-­‐derstand	  the	  reasons	  for	  this	  and	  identify	  biomarkers	  of	  response.	  The	  early	  dis-­‐covery	   of	   PTEN	   activity	   as	   a	   marker	   of	   response	   to	   EGFR	   inhibition	   [6]	   was	  among	  the	  first	  to	  implicate	  bypass	  mechanisms	  in	  the	  acquisition	  of	  resistance,	  but	  reproducing	  these	  findings	  in	  subsequent	  work	  has	  been	  challenging	  [92,	  93].	  Since	  then,	  many	  other	  groups	  have	  investigated	  the	  mechanisms	  of	  resistance	  to	  EGFR	   inhibition	   in	   GBM	   [94-­‐96]	   but	   the	   findings	   remain	   to	   be	   translated	  	  clinically.	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One	  approach	  for	  tackling	  resistance	  or	  lack	  of	  response	  to	  EGFR	  inhibitors	  in	  GBM	  has	  been	  to	  learn	  from	  other	  cancers	  with	  similar	  drivers.	  EGFR	  is	  critically	  important	  to	  oncogenic	  signaling	  in	  tumors	  such	  as	  lung	  adenocarcinoma	  and	  colorectal	  cancer,	  and	  the	  use	  of	  EGFR-­‐targeted	  small	  molecules	  and	  antibodies	  has	  been	  relatively	  successful	  in	  these	  cancers	  [97-­‐99],	  improving	  survival	  by	  up	  to	  a	  year	  even	  though	  acquired	  resistance	  eventually	  emerges.	  On	  the	  other	  hand,	  EGFR	  inhibitors	  in	  GBM	  have	  shown	  little	  survival	  benefit	  in	  the	  clinical	  setting.	  	  What	  are	  the	  differences	  between	  these	  two	  types	  of	  EGFR	  driven	  cancers	  and	  how	  do	  they	  impact	  how	  we	  address	  treatment	  resistance	  in	  GBM?	  	  The	  majority	  of	  EGFR	  mutations	  observed	  in	  lung	  cancer	  occur	  in	  the	  intracellu-­‐lar	  kinase	  domain	  of	  the	  receptor,	  relieving	  the	  receptors	  of	  the	  autoinhibition	  that	  normally	  limits	  activity	  subsequent	  to	  receptor	  dimerization	  and	  causing	  up	  to	  50-­‐fold	  increases	  in	  activity	  [100].	  Reversible	  small	  molecule	  inhibitors	  such	  as	  Gefinitib	  and	  Erlotinib	  bind	  to	  the	  ATP	  binding	  domain	  of	  this	  receptor,	  thus	  in-­‐hibiting	  autophosphorylation	  and	  downstream	  signaling	  [101,	  	  102].	  	  On	  the	  other	  hand,	  EGFR	  mutations	  in	  GBM	  occur	  most	  frequently	  in	  the	  extracel-­‐lular	  domain,	  in	  the	  form	  of	  the	  deletion	  variant	  EGFRvIII.	  This	  mutation	  often	  co-­‐occurs	  with	  EGFR	  amplification,	  resulting	  in	  high	  levels	  of	  both	  EGFR	  WT	  and	  EG-­‐FRvIII,	  and	  the	  two	  have	  been	  hypothesized	  to	  potentiate	  each	  other,	  resulting	  in	  the	  activation	  of	  downstream	  signaling	  pathways.	  Thus,	  utilizing	  inhibitors	  that	  are	  able	  to	  successfully	  reduce	  activity	  of	  the	  EGFRvIII	  variant	  could	  improve	  re-­‐sponse	  in	  this	  subset	  of	  patients	  [7].	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Another	  obstacle	  to	  the	  adequate	  inhibition	  of	  EGFR	  in	  GBM	  is	  the	  presence	  of	  the	  blood	  brain	  barrier,	  which	  may	  prevent	  sufficiently	  high	  concentrations	  of	  inhibi-­‐tor	  from	  reaching	  the	  brain.	  In	  a	  study	  by	  Hegi	  et	  al.,	  patients	  who	  had	  been	  treat-­‐ed	  with	  the	  EGFR	  inhibitor	  gefitinib	  preoperatively	  had	  their	  tumors	  examined	  for	  the	  drug	  after	  its	  removal	  by	  surgery	  [10].	  The	  concentration	  of	  drug	  ob-­‐served	  (4.1µg/g)	  while	  higher	  than	  that	  in	  plasma,	  was	  well	  below	  the	  concentra-­‐tion	  required	  to	  adequately	  inhibit	  EGFR	  phosphorylation	  in	  vitro,	  in	  representa-­‐tive	  cell	  lines	  [13].	  	  Finally,	  one	  class	  of	  resistance	  mechanisms	  arises	  from	  signaling	  pathway	  ro-­‐bustness.	  These	  occur	  as	  a	  consequence	  of	  network	  features	  such	  as	  redundancy,	  feedback	  control	  and	  cross-­‐talk	  between	  proteins	  that	  evolved	  as	  a	  consequence	  of	  their	  granting	  resilience	  to	  organisms	  in	  the	  face	  of	  environmental	  insults,	  but	  that	  are	  co-­‐opted	  by	  the	  evolutionary	  processes	  leading	  to	  cancer.	  One	  way	  to	  disrupt	  these	  sorts	  of	  interactions	  is	  the	  use	  of	  drug	  combinations	  that	  alter	  the	  protein	  activities	  contributing	  to	  a	  phenotype.	  In	  this	  context,	  it	  has	  been	  shown	  taking	  the	  time	  at	  which	  each	  target	  is	  inhibited	  into	  explicit	  consideration	  can	  be	  a	  useful	  strategy.	  Protein	  interactions	  are	  dynamic	  in	  nature	  and	  robustness	  is	  often	  the	  result	  of	  compensatory	  processes	  that	  evolve	  over	  time	  in	  response	  to	  perturbations	  [103].	  	  Thus	  the	  sequential	  treatment	  of	  cancer	  with	  drug	  combina-­‐tions	  has	  been	  more	  effective	  than	  co-­‐treatment	  in	  several	  tumors	  [14,	  	  15,	  	  104]	  	  A	  therapeutic	  strategy	  is	  more	  likely	  to	  be	  effective	  if	  tailored	  to	  the	  constellation	  of	  resistance	  mechanisms	  unique	  to	  EGFR	  activated	  GBM.	  One	  such	  approach	  is	  the	  use	  of	  a	  second	  drug	  in	  combination	  with	  an	  EGFR	  inhibitor	  known	  to	  bind	  effectively	  to	  both	  WT	  and	  vIII	  forms	  of	  EGFR.	  An	  appropriately	  selected	  drug	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could	  act	  synergistically	  with	  the	  EGFR	  inhibitor,	  lowering	  the	  amount	  of	  either	  drug	  required	  to	  levels	  that	  are	  achievable	  within	  GBM	  tumors.	  Successful	  com-­‐binations	  in	  this	  context	  would	  also	  likely	  disrupt	  the	  protein	  interactions	  medi-­‐ating	  signaling	  robustness,	  as	  discussed	  earlier.	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Figure	  6.	  Graphical	  representation	  of	  the	  experimental	  design	  of	  sequen-­‐tial	  synergy	  experiments	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drug	  in	  TNBC	  cell	  lines	  whereas	  the	  reverse	  order	  reduced	  the	  combination’s	  ef-­‐fect.	  	  Similarly,	  in	  two	  large	  studies	  performed	  in	  breast	  cancer,	  glioblastoma	  and	  medulloblastoma	  cell	  lines,	  pretreating	  these	  lines	  with	  obatoclax	  enhanced	  the	  effects	  of	  the	  EGFR	  and	  HER2	  inhibitor	  lapatinib	  in	  PTEN	  deficient	  cell	  lines.	  This	  work	  convincingly	  demonstrated	  the	  inhibition	  of	  processes	  downstream	  of	  the	  targets	  of	  each	  drug.	  However,	  the	  interaction	  of	  their	  effects	  towards	  the	  effects	  observed	  remains	  to	  be	  understood.	  	  Using	  high	  throughput	  phenotypic	  screening	  of	  an	  EGFR	  amplified	  and	  EGFRvIII	  bearing	  tumorsphere	  line	  to	  combinations	  of	  drugs	  that	  include	  lapatinib,	  we	  showed	  that	  lapatinib	  was	  synergistic	  in	  combination	  with	  obatoclax	  and	  RO-­‐31-­‐7549	  and	  that	  these	  drug	  combinations	  were	  effective	  at	  inhibiting	  cell	  viability.	  The	  observed	  efficacy	  of	  drug	  combinations	  is	  dependent	  not	  only	  on	  the	  se-­‐quence	  of	  drug	  administration	  but	  also	  on	  the	  time	  between	  drug	  perturbations.	  Further	  exploration	  of	  the	  combination	  of	  lapatinib	  and	  obatoclax	  in	  other	  EGFR	  altered	  cell	  lines	  (TS600	  with	  a	  single	  EGFR	  gain	  and	  GBM39	  with	  EGFRvIII	  and	  amplification)	  showed	  that	  while	  the	  drug	  combination	  remained	  effective	  and	  synergistic	  in	  all	  cell	  lines,	  its	  dependence	  on	  sequence	  and	  time	  delay	  was	  cell-­‐line	  specific.	  We	  performed	  a	  protein	  array	  experiment	  that	  measured	  the	  re-­‐sponses	  of	  60	  proteins	  and	  phosphoproteins	  to	  lapatinib	  and	  obatoclax	  adminis-­‐tered	  alone	  as	  well	  as	  in	  simultaneous	  and	  sequential	  combinations	  to	  explore	  the	  protein	  correlates	  of	  our	  phenotypic	  observations.	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Experiments	  and	  results	  	  
I.	  Diversity	  of	  temporal	  dynamics	  after	  single	  drug	  perturbation	  of	  TS676	  
	  
Rationale	  Successfully	  perturbing	  a	  signaling	  network	  with	  sequentially	  administered	  drugs	  is	  critically	  dependent	  on	  the	  selection	  of	  appropriate	  times	  at	  which	  to	  perturb	  the	  selected	  targets	  [14].	  	  We	  reasoned	  that	  observing	  the	  dynamics	  of	  protein	  response	  to	  single	  drugs	  that	  we	  were	  interested	  in	  using	  in	  combination	  with	  one	  another	  would	  assist	  the	  prospective	  selection	  of	  optimal	  time	  delays.	  We	  began	  our	  analyses	  with	  the	  GBM	  tumorsphere	  line	  TS676,	  an	  EGFR	  amplified	  cell	  line	  bearing	  the	  EGFRvIII	  variant	  in	  addition	  to	  an	  MDM4	  amplification	  and	  a	  CDKN2A	  deletion.	  We	  perturbed	  this	  cell	  line	  with	  7	  single	  drugs	  and	  the	  ligand	  EGF	  at	  10	  time	  points	  spaced	  exponentially	  between	  6	  minutes	  and	  2days.	  The	  selection	  of	  time	  points	  was	  based	  on	  observations	  from	  prior	  work	  showing	  that	  phosphoprotein	  responses	  to	  perturbants	  can	  manifest	  within	  minutes	  of	  treat-­‐ment	  [105,	  	  106],	  whereas	  total	  protein	  level	  changes,	  modified	  by	  longer	  acting	  phenomena	  such	  as	  transcription	  factor	  mediated	  gene	  regulation	  that	  occur	  over	  a	  period	  of	  hours	  to	  days.	  	  Further,	  the	  concentrations	  of	  the	  drugs	  applied	  corre-­‐sponded	  closely	  to	  their	  IC-­‐50	  values,	  obtained	  from	  our	  evaluations	  in-­‐house	  as	  well	  as	  from	  the	  literature,	  reported	  in	  table	  2.	  In	  many	  cases,	  our	  selected	  con-­‐centrations	  were	  below	  those	  frequently	  chosen	  in	  experiments	  focused	  on	  de-­‐tecting	  the	  phenotypic	  effects	  of	  these	  drugs.	  As	  our	  intent	  in	  this	  experiment	  was	  to	  identify	  proteins	  whose	  activities	  changed	  specifically	  in	  response	  to	  each	  drug	  applied,	  we	  used	  them	  in	  regimes	  that	  we	  anticipated	  would	  minimize	  promiscu-­‐ous	  binding	  and	  other	  effects	  related	  to	  non-­‐specificity.	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Experiment	  protocol	  Beginning	  at	  two	  passages	  before	  each	  experiment,	  cells	  were	  grown	  in	  flasks	  pre-­‐coated	  with	  laminin	  (Sigma	  L2020)	  to	  enable	  the	  growth	  of	  tumorspheres	  as	  adherent	  monolayers.	  We	  used	  DME-­‐F12	  medium	  supplemented	  with	  B27,	  EGF	  and	  FGF	  (20ng/ml	  each)	  and	  heparin.	  Cells	  were	  seeded	  in	  laminin	  coated	  6	  well	  plates	  12	  hours	  prior	  to	  drug	  application.	  At	  the	  selected	  times	  after	  drug	  applica-­‐tion,	  the	  plates	  were	  transferred	  to	  an	  ice-­‐trough	  where	  the	  cells	  were	  rapidly	  scraped	  off	  each	  well,	  pelleted	  and	  frozen.	  Subsequently	  they	  were	  lysed	  and	  the	  protein	  fraction	  of	  the	  lysate	  was	  diluted	  appropriately	  for	  analysis	  using	  reverse	  phase	  protein	  arrays.	  	  
Data	  acquisition	  and	  normalization	  Protein	  activities	  obtained	  using	  RPPA	  are	  reported	  relative	  to	  each	  other	  and	  to	  positive	  control	  spots	  printed	  uniformly	  on	  each	  slide.	  This	  allows	  the	  relative	  quantification	  of	  a	  protein’s	  activity	  across	  treatments	  or	  conditions.	  We	  first	  ap-­‐ply	  a	  spatial	  normalization	  routine	  to	  the	  raw	  intensities	  obtained	  that	  removes	  spatial	  non-­‐uniformity	  imposed	  on	  the	  measurements	  by	  factors	  such	  as	  uneven	  exposure	  of	  slides	  to	  experimental	  reagents	  	  [17].	  Next,	  to	  map	  the	  quantified	  in-­‐tensities	  to	  relative	  protein	  concentrations,	  we	  use	  a	  joint	  estimation	  method	  called	  SuperCurve	  [107]	  that	  fits	  all	  the	  sample	  intensities	  on	  each	  slide	  to	  a	  3	  pa-­‐rameter	  logistic	  equation.	  	  Thus,	  each	  slide	  is	  associated	  with	  both	  global	  parameters	  and	  protein	  concentra-­‐tion	  estimates.	  	  The	  estimates	  obtained	  across	  all	  proteins	  are	  now	  normalized	  by	  median	  normalization	  and	  then	  rescaled	  by	  dividing	  them	  by	  the	  second	  median	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Results	  
	  We	  observed	  that	  proteins	  fell	  into	  three	  broad	  categories,	  displaying	  local	  max-­‐ima	  and	  minima	  early	  (6min-­‐0.5h),	  intermediately	  (1.5h-­‐6hours)	  or	  late	  (>12h)	  after	  treatment.	  To	  identify	  those	  proteins	  whose	  activities	  were	  the	  most	  affect-­‐ed	  by	  treatment,	  we	  computed	  the	  area	  under	  the	  time	  series	  curve	  (AUC)	  for	  each	  protein	  in	  response	  to	  every	  treatment	  and	  compared	  this	  to	  the	  corre-­‐sponding	  AUC	  of	  that	  protein’s	  time	  course	  in	  the	  absence	  of	  treatment.	  We	  iden-­‐tified	  proteins	  showing	  an	  absolute	  change	  in	  AUC	  of	  25%	  or	  greater	  compared	  to	  untreated	  control	  as	  ‘responders’	  if	  this	  response	  was	  statistically	  significant	  across	  all	  three	  replicates	  of	  the	  time	  course	  measured.	  	  For	  this,	  we	  used	  a	  two	  tailed	  t-­‐test,	  assessing	  the	  level	  of	  significance	  of	  the	  p-­‐values	  obtained	  by	  com-­‐paring	  them	  with	  the	  level	  of	  significance	  obtained	  from	  a	  1%	  FDR-­‐permissive	  Storey	  test.	  The	  list	  of	  responders	  across	  each	  protein	  is	  in	  Table	  3.	  	  Some	  of	  our	  specific	  observations	  were	  (a) Lapatinib	  treatment	  is	  associated	  with	  the	  late	  induction	  of	  BIM	  in	  TS676	  (b) Obatoclax	  and	  PKCi	  are	  associated	  with	  an	  intermediate	  induction	  of	  pAKT-­‐pS473.	  Both	  Western	  Blots	  and	  Zeptosens	  RPPA	  data	  validated	  the	  latter	  of	  these	  observations.	  However,	  in	  both	  cases,	  pAKT	  continued	  to	  increase	  after	  6	  hours	  up	  to	  24hours.	  This	  discrepancy	  could	  be	  because	  of	  experimental	  error	  in	  the	  first	  RPPA	  experiment,	  where	  we	  had	  to	  deal	  with	  multiple	  samples	  and	  temperature	  or	  other	  effects	  could	  have	  introduced	  noise	  in-­‐to	  the	  results.	  Further	  the	  MDA	  RPPA	  platform	  is	  inherently	  noisy	  because	  of	  factors	  discussed	  earlier.	  As	  the	  western	  blots	  were	  repeated	  and	  Zep-­‐
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tosens	  arrays	  are	  less	  error	  prone	  than	  MDA-­‐RPPA,	  we	  are	  confident	  that	  pAKT	  levels	  rise	  over	  the	  period	  of	  a	  day	  in	  response	  to	  obatoclax.	  	  Changes	  in	  the	  levels	  of	  proteins	  downstream	  of	  the	  targets	  of	  lapatinib	  and	  obatoclax	  	  observed	  between	  6	  minutes	  and	  1	  day	  after	  inhibition.	  lapatinib	  treatment	  leads	  to	  the	  inhibition	  of	  pAKT	  whereas	  obatoclax	  potentiates	  it.	  This	  observation	  was	  validated	  by	  subsequent	  experiments	  including	  Western	  Blots	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Figure	  8.	  Responses	  of	  the	  proteins	  pAKT	  and	  BIM	  to	  single	  drug	  applica-­‐tion	  with	  lapatinib	  and	  Obatoclax	  






Table	  4.	  Statistically	  significant	  responders	  to	  single	  drug	  treatments	  identi-­‐fied	  by	  comparing	  the	  ratio	  of	  the	  area	  under	  each	  protein’s	  time	  series	  curve	  to	  that	  of	  the	  protein’s	  untreated	  control	  curve.	  A	  two-­‐tailed	  t-­‐test	  was	  used	  to	  determine	  significance	  across	  3	  replicates	  
TIME ANTIBODY TREATMENT AUC.ratio p5value MEAN.DIFF
med p38_pT180_Y182.R.VObatoclax 1.6277686 0.0011 :896.739
early p38_pT180_Y182.R.VObatoclax 1.4410454 0.0008 :1284.38
early MEK1_pS217_S221.R.VObatoclax 1.4064922 0.0016 :980.234
early Rab11.R.E Lapatinib 1.3574756 0.0016 :808.125
med MEK1_pS217_S221.R.VRO:31:7549 1.354577 0.0014 :733.933
early C.Raf_pS338.R.E Obatoclax 1.3144994 0.0014 :3109.14
late Rab11.R.E Obatoclax 1.3132368 0.0006 :243.664
med c.Kit.R.V Temozolomide 1.2987036 0.0008 :598.4
early Rab11.R.E PD0332991 1.2917168 0.0015 :808.766
med JNK_pT183_pT185.R.VObatoclax 1.2883029 0.0019 :651.191
early Rab11.R.E Curcumin 1.2830512 0.0015 :808.85
med c.Kit.R.V Curcumin 1.2811378 0.0006 :601.052
med MEK1_pS217_S221.R.VCurcumin 1.2807678 0.0016 :748.594
med MEK1_pS217_S221.R.VBEZ:235 1.2778012 0.0014 :749.183
late PKC.delta_pS664.R.VLapatinib 1.2777283 0.0002 :1415.04
early PI3K.p110.alpha.R.CLapatinib 1.2740156 0.0002 :1127.41
med p38_pT180_Y182.R.VRO:31:7549 1.2737422 0.0010 :986.039
med Notch1.R.V Obatoclax 1.2705029 0.0007 :1525.91
late HER3_pY1298.R.CBEZ:235 1.2699474 0.0012 :1239.84
med p90RSK_pT359_S363.R.CBEZ:235 1.2647174 0.0008 :1356.96
early c.Kit.R.V Curcumin 1.2638852 0.0001 :782.209
early Rab11.R.E Obatoclax 1.254467 0.0015 :809.129
early Rab11.R.E BEZ:235 1.2544271 0.0016 :809.129
early RBM15.R.V RO:31:7549 0.7499868 0.0008 :25478.3
late Akt.R.V PD0332991 0.7444625 0.0015 :21568.3
med RBM15.R.V Curcumin 0.7365044 0.0009 :21950
early Akt.R.V EGF 0.7338995 0.0012 :32923.8
early RBM15.R.V Obatoclax 0.7305153 0.0008 :25485
early eIF4G.R.C PD0332991 0.7301565 0.0011 :24675.7
early Akt.R.V RO:31:7549 0.7296427 0.0012 :32925.9
overall mTOR_pS2448.R.CRO:31:7549 0.728994 0.0001 :762.2
late Akt.R.V Lapatinib 0.7276539 0.0001 :21833
early Akt.R.V BEZ:235 0.7263001 0.0012 :32927.6
overall Akt.R.V Lapatinib 0.7175975 0.0002 :9402.11
early PRAS40_pT246.R.VBEZ:235 0.7165496 0.0011 :6534.68
med Akt.R.V Lapatinib 0.7153165 0.0016 :27664.5
early RBM15.R.V Curcumin 0.7094862 0.0008 :25492.2
med eIF4G.R.C PD0332991 0.7077669 0.0016 :21118.7
early Akt.R.V PD0332991 0.7032897 0.0012 :32939.2
med TSC1.R.C PD0332991 0.6868866 0.0006 :25309.9
med Akt.R.V BEZ:235 0.6813607 0.0012 :27931.7
late mTOR_pS2448.R.CRO:31:7549 0.6749901 0.0002 :1833.85
late eIF4G.R.C Obatoclax 0.6740922 0.0013 :16368.8
med PRAS40_pT246.R.VBEZ:235 0.6648197 0.0013 :5682.67
early Akt.R.V Obatoclax 0.6647895 0.0012 :32958.6
late Myosin.IIa.pS1943.R.VLapatinib 0.6645339 0.0009 :23250
med eIF4G.R.C BEZ:235 0.6560012 0.0008 :21394.8
overall IGFBP2.R.V BEZ:235 0.6499928 0.0014 :4355.6
early GSK3.alpha.beta_pS21_S9.R.VRO:31:7549 0.647414 0.0016 :2170.22
early Akt.R.V Curcumin 0.646385 0.0012 :32967.8
med Akt.R.V Curcumin 0.6435094 0.0015 :28229.5
late Akt.R.V Obatoclax 0.6416966 0.0014 :23186.8
late Tuberin.R.E Obatoclax 0.6328233 0.0018 :13618
late PRAS40_pT246.R.VObatoclax 0.6281506 0.0013 :4427.85
late mTOR_pS2448.R.CObatoclax 0.6220387 0.0004 :1910.62
early YAP_pS127.R.E RO:31:7549 0.6178186 0.0014 :6124.71
late mTOR_pS2448.R.CBEZ:235 0.5877526 0.0005 :1960.33
overall mTOR_pS2448.R.CBEZ:235 0.5626977 0.0002 :1229.9
med mTOR_pS2448.R.CBEZ:235 0.5309018 0.0011 :2504.97
overall eIF4G.R.C BEZ:235 0.5189625 0.0007 :11975.1
late eIF4G.R.C BEZ:235 0.4522254 0.0011 :19174.8
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II.	  Time	  delay	  dependent	  modulation	  of	  response	  to	  lapatinib	  by	  obatoclax	  	  
	  
Rationale	  We	  looked	  to	  our	  observations	  from	  the	  single	  drug	  time	  series	  responses	  to	  se-­‐lect	  both	  drug	  targets	  and	  delay	  times	  for	  a	  phenotypic	  screen	  aimed	  at	  evaluat-­‐ing	  the	  effects	  of	  a	  set	  of	  sequential	  drug	  combinations.	  	  Based	  on	  our	  observa-­‐tions	  that	  the	  greatest	  number	  of	  observed	  nodes	  changed	  by	  >	  25%	  w.r.t	  un-­‐treated	  control	  during	  the	  intermediate	  time	  period	  (1.5-­‐6h),	  we	  chose	  6h	  as	  one	  of	  the	  delay	  periods	  between	  drug	  applications	  to	  use	  in	  a	  screen.	  To	  incorporate	  effects	  that	  might	  arise	  from	  targeting	  proteins	  that	  have	  equilibrated	  to	  steady	  state	  levels	  imposed	  by	  the	  action	  of	  the	  first	  drug,	  we	  contrasted	  the	  selection	  of	  6h	  with	  a	  second	  delay	  period	  of	  24	  hours.	  	  Drug	  choice	  was	  motivated	  by	  network	  considerations	  such	  as	  the	  proximity	  of	  the	  second	  target	  to	  perceived/prior	  knowledge	  of	  pathway	  structure.	  Thus	  we	  selected	  drugs	  whose	  targets	  were	  proximal	  to	  EGFR,	  the	  target	  of	  lapatinib,	  such	  as	  a	  PI3	  kinase	  inhibitor	  or	  inhibited	  possible	  bypass	  activators,	  such	  as	  a	  PDGFR	  inhibitor.	  We	  selected	  the	  cytotoxic	  drug	  doxorubicin,	  to	  enable	  a	  comparison	  of	  our	  results	  with	  those	  of	  Lee	  et	  al	  [14],	  and	  Curcumin	  -­‐	  a	  drug	  with	  several	  attrac-­‐tive	  targets	  including	  NFkB	  and	  COX-­‐2.	  Finally,	  we	  included	  drugs	  with	  targets	  distant	  from	  EGFR,	  such	  as	  the	  BCL2	  inhibitor	  obatoclax	  and	  the	  STAT3	  inhibitor	  stattic.	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Experiment	  protocol	  Cells	  were	  seeded	  in	  96	  well	  plates	  at	  nearly	  50%	  confluence.	  After	  12	  hours,	  they	  were	  treated	  with	  drugs,	  either	  as	  single	  perturbations,	  or	  in	  sequential	  or	  simultaneous	  combinations	  with	  lapatinib.	  	  After	  3	  days	  from	  the	  first	  treatment,	  cell	  viability	  across	  all	  measured	  conditions	  was	  evaluated	  using	  a	  resazurin	  as-­‐say.	  Cellular	  activity	  under	  each	  condition	  as	  reported	  as	  a	  fraction	  of	  the	  un-­‐treated	  control.	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B then B- Blank
D1 then V - single drug treatment with D1
V then D2 - single drug treatment with D2
D1,D2 then V - synchronous treatment with combination
D1 then D2 - time staggered combination treatment
V then V - No drug control
Fori each treatment performed at t1 and t2, 

















Figure	  9.	  Experimental	  design	  of	  sequential	  drug	  application	  screen	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AK,'6h' AK,'24h' BZ,'6h'''' BZ,'24h' CU,'6h'''' CU,'24h'
CY,'6h' CY,'24h' DF,'6h'''' DF,'24h' DO,'6h'''' DO,'24h'
DS,'6h' DS,'24h' MK,'6h'''' MK,'24h' NT,'6h'''' NT,'24h'
OB,'6h' OB,'24h' PD,'6h'''' PD,'24h' ME,'6h''''
CD,'6h' CD,'24h' RO,'6h'''' RO,'24h' ST,'6h'''' ST,'24h'
SU,'6h' SU,'24h' TE,'6h'''' TE,'24h' ZS,'6h'''' ZS,'24h'
ME,'24h''''
18'drug'pairs'administered'sequen:ally'or'simultaneously'with'Lapa:nib'
Figure	  10.	  Fractional	  cellular	  viability	  resulting	  from	  simultaneous	  and	  se-­‐quential	  drug	  combinations	  in	  a	  screening	  experiment	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Both%Obatoclax%(BCL2i)%and%RO53157549%(PKCi)%cause%cell%death%in%select%conAigurations% of% their% combination% with% Lapatinib.% RO53157549's%effectiveness%is%greatest%when%administered%6h%before%Lapatinib%whereas%Obatoclax's%is%maximized%at%24h%before%LapatinibFigure	  11.	  Fractional	  cell	  death	  in	  response	  to	  simultaneous	  and	  sequential	  combinations	  of	  Lapatinib	  with	  Obatoclax	  and	  RO-­‐31-­‐7549	  respectively	  in	  tumorsphere	  line	  TS676	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PKC	  inhibitor	  preceded	  lapatinib	  by	  6h.	  	  
(iii)	  Differential	  effects	  of	  lapatinib	  and	  obatoclax	  on	  GBM	  cell	  lines	  with	  
variable	  EGFR	  status	  
Rationale	  To	  investigate	  whether	  the	  efficacy	  and	  synergy	  observed	  with	  lapatinib	  and	  obatoclax	  extended	  to	  other	  GBM	  tumorsphere	  lines,	  and	  the	  dependence	  of	  the	  observations	  on	  the	  EGFR	  status	  of	  the	  population,	  we	  tested	  the	  effect	  of	  these	  drugs	  on	  two	  additional	  cell	  lines	  –	  TS600,	  a	  line	  bearing	  an	  EGFR	  gain	  and	  GBM39,	  an	  EGFRvIII	  mutation	  and	  amplification	  bearing	  line	  that	  the	  lab	  of	  Dr.	  Frank	  Furnari	  kindly	  shared	  with	  us	  	  
Experiment	  protocol	  Cells	  were	  seeded	  in	  24	  well	  plates,	  at	  uniform	  confluence	  near	  40%.	  They	  were	  treated	  with	  drugs	  starting	  one	  day	  after	  cell	  seeding,	  and	  were	  imaged	  every	  2h	  for	  the	  next	  3-­‐4	  days.	  Per	  user	  defined	  settings,	  Incucyte	  ZOOM™	  reported	  the	  av-­‐erage	  confluence	  from	  a	  total	  of	  9	  images	  spanning	  the	  area	  of	  the	  	  well.	  This	  choice	  reduced	  the	  variation	  arising	  from	  any	  cellular	  unevenness	  that	  might	  re-­‐sult	  from	  temperature	  or	  motion	  effects.	  	  	  
Results	  	  
(a)	  Pretreatment	  with	  obatoclax	  is	  beneficial	  in	  TS676	  but	  not	  in	  TS600	  or	  
GBM39	  The	  combination	  reduced	  the	  observed	  cellular	  density	   in	  both	  cell	   lines	  syner-­‐gistically	  but	  delay	  was	  mildly	  beneficial	  in	  TS600	  (in	  the	  condition	  where	  lapa-­‐tinib	  preceded	  obatoclax)	  and	  increased	  rate	  of	  cell	  growth	  in	  GBM39.	  As	  images	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Pretreatment with Obatoclax before Lapatinib favors cell death in TS676 
CELL DENSITY MEASUREMENTS OVER TIME
GROWTH RATE EVALUATED BETWEEN 68-72h (~3 Days)
Lapatinib O→L (12h)L+O Lapatinib O→L (12h)L+O Lapatinib O→L (12h)L+O
Figure	  12.	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(c) Obatoclax	  and	  lapatinib	  cause	  distinct	  morphological	  changes	  in	  
TS676	  upon	  exposure	  to	  different	  treatment	  regimens	  
	  
These	  qualitative	  observations	  motivate	  the	  use	  of	  addditional	  quantitative	  methods	  for	  the	  acquisition	  of	  a	  greater	  number	  of	  therapeutically	  relevant	  phe-­‐notypic	  responses	  from	  these	  data.	  	  	  
	  
(iv)	  Protein	  response	  to	  sequential	  and	  single	  treatments	  with	  Western	  
Blots	  reveals	  time	  dependent	  potentiation	  of	  pAKT	  by	  obatoclax	  
	  We	  next	  investigated	  the	  effects	  of	  these	  treatments	  on	  the	  levels	  of	  pAKT-­‐pS473	  as	  measured	  using	  Western	  Blots.	  We	  wanted	  to	  explore	  whether	  there	  were	  any	  obvious	  protein	  level	  differences	  between	  the	  response	  of	  these	  cell	  lines	  to	  lapa-­‐




Changes in TS676 cell density and morphology over time as observed using the Incucyte ZOOM.








 sparse and 
display elongationFigure	  13.	  Changes	  in	  TS676	  cell	  density	  and	  morphology	  in	  response	  to	  different	  drug	  treatments	  as	  observed	  with	  Incucyte	  ZOOM™	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Figure	  14.	  Protein	  response	  to	  sequential	  and	  single	  treatment	  with	  lapatinib	  and	  obatoclax	  in	  TS676	  reveals	  time	  dependent	  potentiation	  of	  pAKT	  by	  Obatoclax	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over	   ice	   and	   the	  pellets	   obtained	  were	   lysed	  with	   a	  RIPA	  based	  buffer.	   Protein	  extracts	  were	  stabilized	  in	  SDS	  and	  2-­‐mercaptoethanol	  and	  loaded	  into	  the	  wells	  of	  a	  4-­‐15%	  western	  blot	  gel.	  After	  the	  proteins	  were	  run,	  they	  were	  transferred	  to	  a	  nitrocellulose	  membrane	  and	  imaged.	  	  
	  
(v)	  Protein	  correlates	  of	  response	  to	  single,	  simultaneous	  and	  sequential	  
treatment	  in	  TS676	  and	  TS600.	  	  	  
Rationale	  The	  behavior	  of	  pAKT	  in	  response	  to	  the	  treatment	  regimens	  we	  tested	  was	  un-­‐expected.	  	  To	  our	  knowledge,	  the	  time	  dependent	  potentiation	  of	  pAKT	  by	  BCL2	  inhibitors	   behavior	   has	   not	   yet	   been	   reported	   in	   any	   other	   cell	   line	   or	   system.	  Prior	   knowledge	   about	   the	   pathways	   that	   connect	   the	   targets	   of	   lapatinib	   and	  obatoclax	   indicates	   that	   RTK	   activation	   leading	   to	   the	   phosphorylation	   of	   AKT	  can	   inhibit	   apoptosis	   by	   inhibiting	   a	   family	   of	   FOXOs	   including	   FOXO3a	   [108,	  109],	   proteins	   that	   transcriptionally	   activate	   diverse	   pro-­‐apoptotic	   pathway	  members.	  In	  this	  paradigm,	  AKT	  activity	  can	  affect	  the	  level	  of	  apoptotic	  proteins	  accessible	  to	  a	  second	  drug	  targeting	  them,	  such	  as	  obatoclax.	  Further,	  the	  com-­‐bination	   of	   lapatnib	   and	   obatoclax	   has	   been	   shown	   to	   lead	   to	   autophagic	   re-­‐sponses	   [110,	   	   111]	   but	   the	   contribution	   of	   each	   drug	   towards	   the	   effects	   ob-­‐served	  remains	  to	  be	  understood.	  	  Towards	  explaining	  the	  effect	  of	  obatoclax	  on	  AKT	  mediated	  signaling	  and	  its	  ef-­‐fect	  on	  the	  observed	  synergy,	  we	  investigated	  the	  time	  dependent	  behavior	  of	  46	  proteins	   in	   response	   to	   the	   drugs	   administered	   singly,	   simultaneously	   and	   se-­‐quentially	   in	  both	  orders,	  with	   a	   time	  delay	  of	  12h,	  which	   corresponded	   to	   the	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time	   interval	   at	   which	   the	   observed	   effect	   of	   the	   combination	   was	   maximized	  when	   obatoclax	   preceded	   lapatinib	   in	   TS676.	   We	   selected	   the	   time	   points	   at	  which	  to	  capture	  protein	  profiles	  based	  on	  our	  prior	  experience	  with	  these	  lines.	  To	  enable	  to	  detection	  of	  slow	  and	  sustained	  changes	  in	  protein	  levels,	  we	  incor-­‐porated	  cell	   collection	  every	  12	  hours	  after	   treatment,	  up	   to	  36	  hours.	  Further,	  for	  each	  treatment	  applied,	  we	  collected	  additional	  samples	  15	  minutes	  and	  1.5h	  into	  treatment,	  to	  observe	  early	  phosphoprotein	  response	  to	  these	  inhibitions.	  	  
	  
Protocol	  To	  perform	  this	  experiment,	  we	  used	  the	  Zeptosens	  protein	  array	  system	  de-­‐scribed	  earlier	  in	  this	  thesis.	  Samples	  were	  prepared	  in	  manner	  similar	  to	  that	  for	  Western	  Blots.	  Cell	  pellets	  were	  lysed	  in	  a	  Urea	  based	  buffer	  and	  robotically	  spot-­‐ted	  at	  four	  dilutions	  and	  3	  biological	  replicates	  each	  onto	  the	  surface	  of	  Zeptosens	  
Figure	  15.	  Design	  of	  experiment	  to	  measure	  protein	  level	  changes	  in	  re-­‐sponse	  to	  sequential	  and	  simultaneous	  treatment	  with	  lapatinib	  and	  Obato-­‐clax	  in	  TS676	  and	  TS600	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glass	  slides.	  The	  relative	  protein	  activity	  of	  each	  sample	  relative	  to	  positive	  con-­‐trol	  spots	  on	  each	  slides	  was	  quantified	  and	  reported.	  Examples	  of	  the	  time	  courses	  obtained	  over	  the	  conditions	  tested	  are	  in	  the	  figure	  overleaf.	  	  	  
Results	  and	  Discussion	  The	  data	  from	  this	  experiment	  lead	  us	  to	  a	  few	  qualitative	  observations.	  The	  se-­‐quential	  treatment	  of	  T676	  with	  obatoclax	  followed	  by	  lapatinib	  12	  hours	  later,	  which	  was	  also	  the	  most	  effective	  treatment	  in	  this	  cell	  line,	  displayed	  the	  highest	  cleaved	  caspase	  3	  levels	  at	  the	  end	  of	  treatment.	  This	  observation	  could	  indicate	  that	  lapatinib	  is	  able	  to	  more	  effectively	  engage	  the	  apoptosis	  pathway	  in	  cells	  whose	  state	  is	  altered	  by	  the	  action	  of	  obatoclax.	  In	  addition,	  the	  level	  of	  p38-­‐MAPK	  rises	  in	  TS676,	  most	  noticeably	  in	  response	  to	  obatoclax.	  In	  inhibiting	  the	  mitochondrial	  apoptotic	  machinery,	  obatoclax	  could	  lead	  to	  the	  generation	  of	  re-­‐active	  oxygen	  species	  (ROS)	  [112].	  p38	  MAPK	  is	  a	  stress	  inducible	  kinase	  that	  can	  respond	  to	  ROS	  and	  mediate	  both	  differentiation	  and	  cell	  death	  [113,	  	  114],	  rais-­‐ing	  the	  possibility	  that	  it	  mediates	  the	  effects	  observed	  in	  treatments	  that	  include	  obatoclax.	  	  Prior	  studies	  have	  observed	  the	  induction	  of	  autophagic	  phenotypes	  and	  proteins	  in	  response	  to	  the	  combination	  of	  drugs,	  as	  well	  as	  the	  inhibition	  of	  ERBB	  family	  members	  in	  response	  to	  lapatinib	  and	  its	  combination	  with	  obatoclax	  [110].	  However,	  how	  the	  interaction	  of	  the	  drugs’	  targets	  and	  downstream	  effectors	  leads	  to	  these	  phenotypes	  remains	  to	  be	  understood.	  Further,	  the	  relationship	  between	  combination	  effects	  resulting	  from	  these	  drugs	  and	  the	  genotypes	  of	  GBM	  tumors	  and	  cell	  lines	  has	  not	  been	  studied	  and	  the	  effect	  of	  combined	  EGFR	  and	  PTEN	  status	  on	  the	  combination’s	  ability	  to	  inhibit	  growth	  is	  not	  known.	  This	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is	  particularly	  relevant	  in	  the	  context	  of	  GBM,	  where	  the	  amplification	  of	  EGFR	  with	  PTEN	  inactivation	  is	  a	  frequent	  co-­‐occurrence.	  	  One	  of	  the	  reasons	  why	  the	  role	  of	  EGFR	  status	  on	  drug	  effects	  in	  GBM	  is	  a	  challenging	  area	  of	  study	  in	  cell-­‐lines	  is	  that	  the	  EGFR	  amplicon	  can	  be	  lost	  easily	  over	  the	  course	  of	  passaging.	  The	  use	  of	  tumorsphere	  cultures	  in	  early	  passages,	  as	  in	  our	  work,	  may	  enhance	  our	  understanding	  of	  combination	  effects	  by	  retaining	  key	  alterations	  present	  in	  the	  parent	  tumor.	  	  	  One	  of	  the	  open	  questions	  from	  our	  work	  is	  how	  delivery	  order	  and	  timing	  im-­‐pacts	  combination	  effects.	  It	  is	  possible	  that	  by	  acting	  12h	  into	  treatment	  rather	  than	  in	  the	  beginning,	  lapatinib	  could	  be	  causing	  the	  inhibition	  of	  MAPK	  and	  AKT	  signaling	  at	  a	  time	  when	  resistance	  mechanisms	  against	  obatoclax	  are	  being	  re-­‐cruited.	  We	  observe	  that	  the	  levels	  of	  both	  total	  and	  phosphorylated	  ERK1/2	  are	  lowered	  at	  24h	  in	  the	  obatoclax	  before	  lapatinib	  (OèL)	  condition,	  whereas	  they	  have	  begun	  to	  rise	  after	  early	  inhibition	  in	  all	  conditions	  where	  lapatinib	  is	  ad-­‐ministered	  early,	  i.e.	  single	  administration	  (L),	  simultaneous	  administration	  (L+O)	  and	  lapatinib	  before	  obatoclax	  (LèO).	  	  While	  individual	  observations	  con-­‐sistent	  with	  known	  pathway	  biology	  can	  aid	  our	  understanding	  of	  the	  mechanism	  of	  a	  drug	  or	  combinations,	  a	  network	  view	  of	  responses	  to	  perturbation	  can	  be	  beneficial.	  A	  goal	  of	  network	  analysis	  would	  be	  to	  quantitatively	  relate	  the	  pro-­‐tein	  targets	  of	  a	  perturbation	  to	  the	  oncogenic	  phenotypes	  observed,	  through	  downstream	  effectors	  of	  each	  protein	  target.	  Identifying	  both	  the	  nodes	  and	  edg-­‐es	  in	  a	  network	  that	  are	  altered	  in	  the	  GBM	  tumorsphere	  lines	  of	  interest,	  and	  how	  these	  are	  altered	  by	  drugs,	  could	  lead	  to	  an	  understanding	  of	  the	  genetic	  context	  in	  which	  the	  drug	  combinations	  we	  studied	  are	  the	  most	  effective,	  and	  subsequent	  cohort	  studies	  in	  non-­‐human	  animals	  and	  clinical	  trials.	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Future	  work	  We	  have	  begun	  more	  detailed	  quantitative	  analyses	  of	  the	  data	  acquired.	  A	  useful	  method	  by	  which	  to	  identify	  correlations	  in	  complex	  multivariate	  data	  is	  that	  of	  partial	  correlations.	  The	  partial	  correlation	  between	  sets	  of	  variables,	  observed	  over	  a	  series	  of	  conditions,	  can	  provide	  insight	  into	  direct	  associations	  that	  drive	  system	  behavior	  [115].	  In	  our	  data,	  because	  the	  protein	  levels	  observed	  at	  vari-­‐ous	  points	  along	  a	  time	  course	  are	  correlated	  to	  one	  another,	  using	  naïve	  partial	  correlation	  methods	  that	  do	  not	  apply	  to	  time	  course	  data	  can	  be	  misleading.	  An	  effort	  by	  the	  lab	  of	  Dr.	  Korbinian	  Strimmer[116],	  to	  evaluate	  dynamical	  partial	  correlations	  that	  exist	  within	  time	  series	  data	  is	  available	  as	  the	  R	  package	  GeneNet.	  Applying	  this	  method	  to	  our	  data	  has	  demonstrated	  differences	  be-­‐tween	  the	  protein	  correlations	  observed	  between	  cell	  lines	  and	  between	  the	  dif-­‐ferent	  treatments	  and	  regimens	  (data	  not	  shown).	  Suggested	  next	  steps	  are	  gen-­‐erating	  hypotheses	  computationally,	  validating	  the	  observations	  using	  appropri-­‐ate	  methods	  such	  as	  permutation	  tests	  and	  ranking	  the	  observations	  in	  order	  of	  their	  magnitude	  and	  statistical	  significance,	  and	  subsequently	  testing	  them	  in	  the	  lab.	  We	  hope	  that	  this	  work	  will	  help	  point	  us	  to	  the	  proteins	  that	  mediate	  the	  ef-­‐fects	  of	  obatoclax	  pretreatment	  on	  the	  efficacy	  of	  lapatinib	  or	  nominate	  addition-­‐al	  targets	  that,	  in	  conjunction	  with	  lapatinib	  and	  obatoclax,	  may	  lead	  to	  effective	  treatments	  for	  EGFR	  amplified	  and	  PTEN	  deficient	  GBMs,	  which	  constitute	  a	  common	  and	  aggressive	  variant	  of	  primary	  glioblastoma.	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cleaved CASP3 time course p38 MAPK time course
pERK1/2 (pThr 202, Thr185) time course ERK1/2 time course 
Figure	  16.	  Time	  course	  of	  cleaved	  CASP3,	  p38	  MAPK,	  and	  total	  and	  phosphor-­‐ylated	  ERK1/2	  in	  response	  to	  various	  regimens	  of	  lapatinib	  and/or	  Obatoclax	  in	  TS676	  and	  TS600	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APPENDIX	  Spatial	  Normalization	  of	  Reverse	  Phase	  Protein	  array	  data	  	  This	  work	  was	  published	  in	  PLoS	  One	  in	  2014	  and	  was	  joint	  work	  with	  other	  au-­‐thors.	  I	  developed	  the	  method,	  wrote	  the	  code	  and	  all	  the	  figures.	  Evan	  Molinelli	  provided	  writing	  assistance.	  The	  experiments	  were	  performed	  by	  Martin	  Miller	  and	  Weiqing	  Wang,	  in	  collaboration	  with	  the	  listed	  members	  of	  the	  M.D.	  Ander-­‐son	  RPPA	  core	  facility	  and	  Systems	  Biology	  department.	  Chris	  Sander	  	  and	  Martin	  Miller	  advised	  me	  on	  the	  design	  of	  the	  experiments	  and	  analyses	  performed.	  	  	  Poorvi	  Kaushik1*,	  Evan	  J	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  L	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  Wang1,	  Anil	  Korkut1,	  Wenbin	  Liu3,	  Zhenlin	  Ju3,	  Yiling	  Lu2,	  Gordon	  Mills2,	  Chris	  Sander1.	  1	  Computational	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  Center,	  Memorial	  Sloan-­‐Kettering	  Cancer	  Center,	  New	  York,	  NY,	  USA,	  2	  Department	  of	  Systems	  Biology,	  The	  University	  of	  Texas	  M.	  D.	  Anderson	  Cancer	  Center,	  Houston,	  Texas,	  USA.	  3	  Division	  of	  Quantitative	  Sciences,	  The	  University	  of	  Texas	  M.	  D.	  Anderson	  Cancer	  Cen-­‐ter,	  Houston,	  Texas,	  USA.	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  Author	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Abstract	  Reverse	   phase	   protein	   arrays	   (RPPA)	   are	   an	   efficient,	   high-­‐throughput,	  cost-­‐effective	  method	  for	  the	  quantification	  of	  specific	  proteins	  in	  complex	  biological	   samples.	  The	  quality	  of	  RPPA	  data	  may	  be	  affected	  by	  various	  sources	  of	  error.	  One	  of	  these,	  spatial	  variation,	  is	  caused	  by	  uneven	  expo-­‐sure	  of	  different	  parts	  of	  an	  RPPA	  slide	  to	  the	  reagents	  used	  in	  protein	  de-­‐tection.	  	  We	  present	  a	  method	  for	  the	  determination	  and	  correction	  of	  sys-­‐tematic	  spatial	  variation	  in	  RPPA	  slides	  using	  positive	  control	  spots	  print-­‐ed	  on	   each	   slide.	   The	  method	  uses	   a	   simple	  bi-­‐linear	   interpolation	   tech-­‐nique	   to	   obtain	   a	   surface	   representing	   the	   spatial	   variation	   occurring	  across	  the	  dimensions	  of	  a	  slide.	  This	  surface	   is	  used	  to	  calculate	  correc-­‐tion	   factors	   that	  can	  normalize	   the	  relative	  protein	  concentrations	  of	   the	  samples	   on	   each	   slide.	   The	   adoption	   of	   the	  method	   results	   in	   increased	  agreement	   between	   technical	   and	   biological	   replicates	   of	   various	   tumor	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and	  cell-­‐line	  derived	  samples.	  Further,	   in	  data	   from	  a	   study	  of	   the	  mela-­‐noma	  cell-­‐line	  SKMEL-­‐133,	  several	  slides	  that	  had	  previously	  been	  reject-­‐ed	  because	  they	  had	  a	  coefficient	  of	  variation	  (CV)	  greater	  than	  15%,	  are	  rescued	  by	  reduction	  of	  CV	  below	  this	  threshold	  in	  each	  case.	  The	  method	  is	   implemented	   in	   the	  R	  statistical	  programing	   language.	   It	   is	  compatible	  with	  MicroVigene	  and	  SuperCurve,	  packages	  commonly	  used	  in	  RPPA	  data	  analysis.	  The	  method	  is	  made	  available,	  along	  with	  suggestions	  for	  imple-­‐mentation,	  at	  http://bitbucket.org/rppa_preprocess/rppa_preprocess/src	  	  
Introduction	  In	   the	   last	   decade,	   the	   study	   of	   cancer	   biology	   has	   been	   accelerated	   by	  many	   technological	   advances,	   enabling	   analyses	   of	   the	   genome	   at	   both	  high	  resolution	  and	  throughput.	  This	  has	  led	  to	  the	  identification	  of	  muta-­‐tions	   and	   biomarkers	   specific	   to	   various	   cancer	   types	   and	   patient	   sub-­‐groups.	  However,	  clinical	  trials	  of	  targeted	  therapy	  guided	  by	  these	  stud-­‐ies	  have	  met	  with	   less	   success	   [117,	   118].	  One	  of	   the	   reasons	   for	   this	   is	  that	  while	  the	  causes	  of	  cancer	  are	  genetic,	  they	  result	  in	  cellular	  malfunc-­‐tion	  at	  the	  level	  of	  proteins.	  While	  changes	  in	  each	  level	  may	  be	  observed	  discretely,	   they	  are	  related	   intimately	  through	  processes	  such	  as	  transla-­‐tion	  of	  mRNA	  to	  protein	  and	  the	  control	  of	  gene	  transcription	  by	  proteins.	  Further,	   proteins	   can	   interact	  with	  metabolites	  post-­‐translationally.	  This	  increases	   the	   complexity	   of	   the	   proteome	   via	   the	   existence	   of	   multiple	  forms	  of	   –	   e.g.	   phosphorylated,	   nitrosylated	   and	  methylated	  –	  molecules	  that	   vary	   in	   function.	   There	   is	   hence	   a	   need	   for	   reliable	   and	   affordable	  methods	   for	   protein	  measurement,	   at	   a	   scale	   capable	   of	   complementing	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today’s	   genomics	   studies,	   so	   that	   together,	   they	   may	   reveal	   the	   mecha-­‐nisms	  driving	  cancer.	  	  Reverse	   phase	   protein	   array	   (RPPA)	   technology	   is	  a	   powerful	   technique	  for	  measuring	   the	   activities	   of	   proteins	   from	   tissue-­‐	   and	   cell-­‐derived	   ly-­‐sate.	   It	   is	  an	   inexpensive,	  high	  throughput,	  quantitative	  method	  with	   low	  sample	   requirements,	  making	   it	   ideal	   for	   large-­‐scale	   proteomic	   profiling	  studies.	   In	  RPPA,	  small	  (~µl)	  amounts	  of	   lysate	  extracted	  from	  biological	  samples	   under	   study	   are	   evenly	   spotted	   onto	   the	   surface	   of	   glass	   slides	  coated	  with	   an	   absorbent	  material	   such	   as	   nitrocellulose.	   A	   single	  RPPA	  slide	  of	  2cm×5cm	  can	  be	  used	   to	  simultaneously	  measure	   the	   levels	  of	  a	  protein	   in	   thousands	   of	   samples	   at	   a	   time,	   using	   an	   automated	   and	   effi-­‐cient	   procedure	   that	   can	   be	   scaled	   up	   to	   hundreds	   of	   proteins	   [66,	   119,	  120].	  Each	  slide	  is	  probed	  with	  a	  primary	  antibody	  against	  the	  protein	  of	  interest,	  sensitive	  to	  pg-­‐ng	  of	  protein	  [121],	  followed	  by	  a	  secondary	  anti-­‐body.	  A	  colorimetric	  or	  fluorescent	  signal	  is	  then	  generated,	  in	  proportion	  with	   the	  secondary	  antibody	  bound,	  and	  may	  be	  quantified	   to	  yield	  esti-­‐mates	  of	  relative	  protein	  concentration	  in	  each	  sample.	  	  RPPA	  design	  has	  several	  advantages	  over	  existing	  methods	  for	  protein	  de-­‐tection.	  Unlike	  methods	  such	  as	  Western	  Blotting	  and	  2D-­‐Gel	  Electropho-­‐resis,	  RPPA	  has	  high	  throughput	  and	  low	  sample	  requirements.	  While	  oth-­‐er	  assays	  such	  as	  multiplexed	  flow-­‐cytometry	  and	  microsphere-­‐based	  as-­‐says	   retain	   some	   of	   these	   advantages,	   they	   are	   far	  more	   expensive	   than	  RPPA	  and	  are	  often	  more	  labor	  intensive	  [122].	  Mass	  spectroscopy	  (MS),	  which	  is	  another	  method	  used	  in	  large-­‐scale	  protein	  level	  studies,	  can	  ana-­‐
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lyze	  the	  proteins	  in	  a	  sample	  using	  both	  unbiased	  and	  targeted	  approach-­‐es.	   However,	   current	  methods	   for	  MS	   require	   high	   sample	   volumes	   and	  the	  time	  required	  for	  sample	  analysis	  can	  be	  high.	  Reverse	  Phase	  Protein	  Arrays	   have	   enabled	   studies	   of	   protein	   networks	   implicated	   in	   different	  cancers	  [123,	  124],	   infectious	  disease	  [125]	  and	  the	  responses	  of	  cells	   to	  various	  drugs	  [126-­‐128].	  However,	  many	  of	  the	  factors	  that	  make	  RPPA	  an	  appropriate	   choice	   for	   proteomics	   studies	   also	   introduce	   noise	   into	   the	  data.	   For	   example,	   the	   use	   of	   targeted	   antibodies	   enables	   the	   measure-­‐ment	  of	   low-­‐abundance	  proteins,	  but	  low	  antibody	  specificity	  can	  lead	  to	  promiscuous	   binding	   and	   false	   positives	   [129,	   130].	   Similarly,	   the	   han-­‐dling	  of	  low	  sample	  volumes	  can	  lower	  the	  signal	  to	  noise	  ratio	  of	  the	  re-­‐sults	  [131].	  The	  reliability	  and	  reproducibility	  of	  RPPA	  data	  are	  a	  key	  de-­‐terminant	  of	   the	  utility	  of	   such	  studies.	  We	  examine	  one	   factor	   that	  con-­‐tributes	  to	  noise	  in	  the	  RPPA	  data	  –	  spatial	  heterogeneity	  –	  and	  describe	  a	  method	  for	  correcting	  it,	  thereby	  enhancing	  the	  quality	  of	  the	  data.	  	  	  Spatial	   variation	   in	   RPPA	   slides	   occurs	   due	   to	   unequal	   exposure	   of	   the	  slides	  to	  the	  experimental	  reagents	  used.	  This	  causes	  non-­‐uniform	  signal	  generation,	  resulting	  in	  systematic	  variations	  across	  the	  area	  of	  each	  slide.	  Spatial	  heterogeneity	  is	  obvious	  when	  identical	  samples	  distributed	  over	  a	  slide	   produce	   variable	   signal	   intensities.	   Consequently,	   variance	   across	  identical	  samples	  serves	  as	  a	  reference	  with	  which	  one	  can	  measure	  and	  then	  correct	  errors	  arising	  from	  this	  heterogeneity	  (Fig.	  1).	  We	  show	  that	  spatial	  differences	   affect	   the	   results	  of	  RPPA	  data	  obtained	   from	  diverse	  biological	  datasets.	  We	  use	  a	   simple,	   flexible	  and	  powerful	  2D	   interpola-­‐tion	  method	  to	  normalize	  the	  data,	  resulting	  in	  significantly	  enhanced	  data	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quality	  as	  measured	  by	  improvements	  in	  reproducibility	  and	  the	  signal	  to	  noise	  ratio	  of	  the	  results.	  Also,	  data	  from	  antibodies	  that	  were	  previously	  unusable	  are	  rescued	  with	  the	  method,	  improving	  the	  utility	  of	  the	  studies	  performed.	   R	   code	   for	   the	  method	   is	   provided	   as	   a	   package	   that	   can	   be	  used	   in	   conjunction	  with	  MicroVigene,	   currently	   a	  widely	   used	   platform	  for	  the	  analysis	  of	  RPPA	  data.	  	  	  
	  	  Figure	  1.	  Steps	  in	  the	  acquisition	  and	  processing	  of	  RPPA	  data.	  Cells	  derived	  from	  differ-­‐ent	   in	  vitro	  and	  in	  vivo	  systems	  are	   lysed	  and	  protein	  extracted	  (1).	  Serially	  diluted	  ex-­‐tracts	  are	  printed	  onto	  the	  surface	  of	  slides	  (2)	  where	  primary	  and	  secondary	  antibodies	  bind	  to	  the	  protein	  of	  interest	  and	  generate	  a	  signal	  proportionate	  to	  the	  amount	  of	  pro-­‐tein	  in	  each	  sample.	  Each	  slide	  can	  accommodate	  5808	  printed	  spots,	  for	  different	  num-­‐bers	  of	  total	  samples	  depending	  on	  the	  layout	  and	  number	  of	  dilutions	  used	  (3).	  Readouts	  obtained	  are	  translated	  to	  sample	  intensities	  after	  scanning	  and	  processing	  of	  the	  slides	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(4).	  Intensities	  of	  positive	  control	  spots	  (horizontal	  yellow	  spots	  in	  (4)),	  which	  are	  tech-­‐nical	  replicates	  of	  each	  other,	  may	  be	  used	  to	  evaluate	  and	  correct	  spatial	  variation	  ob-­‐served	  in	  each	  slide.	  Spatial	  correction	  of	  data	  can	  improve	  data	  quality	  resulting	  in	  bet-­‐ter	  estimates	  of	  relative	  protein	  concentration	  and	   improved	  agreement	  between	   inter-­‐	  and	  intra-­‐slide	  replicates	  from	  various	  experiments.	  	  	  
Materials	  and	  Methods	  
Data	  sets	  analyzed	  using	  normalization	  routine	  RPPA	  data	   for	   this	  study	  were	  obtained	  from	  slides	  printed	  with	  various	  human	   cell-­‐line	   and	   tumor	   derived	   samples	   and	   probed	  with	   antibodies	  specific	   to	   proteins	   relevant	   to	   the	   study.	   The	   details	   of	   the	  method	   are	  provided	  in	  the	  results.	  	  We	  tested	  this	  method	  on	  the	  following	  data	  sets.	  1)	  Set	   A	   -­	   Quality	   control	   samples.	   This	   dataset	  was	   comprised	   of	   16	  slides,	  each	  identically	  printed	  with	  sample	  and	  then	  queried	  with	  a	  single	  primary	  antibody.	  The	  samples	  in	  these	  slides	  were	  obtained	  from	  a	  quali-­‐ty	   control	   study	   performed	   in	   the	   M.D.	   Anderson	   Cancer	   Center	   RPPA	  core-­‐facility	  and	  a	  list	  of	  the	  antibodies	  used	  is	  provided	  in	  supplementary	  table	  S2.	  2)	  Set	   B	   -­	   Human	  melanoma	   cell	   line-­derived	   samples.	  This	  data	   set	  was	  obtained	  from	  experiments	  performed	  in-­‐house	  in	  the	  Sloan	  Kettering	  Institute.	  The	  melanoma	  cell	  line	  SKMEL-­‐133,	  a	  V600EBRAF/PTEN	  null	  mu-­‐tant	  cell	  line	  kindly	  gifted	  to	  us	  by	  Dr.	  David	  Solit,	  MSKCC	  [132],	  was	  per-­‐turbed	  with	  10	  small	  molecule	  inhibitors	  (supplementary	  table	  S1)	  target-­‐ing	   specific	   kinases	   that	   control	   cell	   death	   and	   proliferation.	   Cells	   were	  treated	  with	  each	  drug	  individually	  as	  well	  as	  with	  all	  pairwise	  combina-­‐tions	  of	  the	  drugs.	  Three	  biological	  replicates	  of	  each	  experimental	  condi-­‐tion	  were	   generated,	   constituting	   approximately	   300	   samples	   that	  were	  measured	  with	  RPPA.	  Cell	  lysate	  from	  each	  sample	  was	  spotted	  onto	  slides	  and	  probed	  using	  159	  antibodies	  (supplementary	  table	  S2)	  to	  measure	  the	  quantities	   of	   clinically	   relevant	   proteins	   or	   phospho-­‐proteins	   in	   those	  samples.	   Several	   of	   the	   slides	  were	   probed	  with	   the	   same	   antibody	   2-­‐3	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times,	   resulting	   in	   a	   total	   of	   238	   slides	   and	  53	   antibodies	  with	   replicate	  slides.	  	  3)	  Set	  C	  –	  Miscellaneous	  anonymized	  samples.	  A	  data	  set	  comprised	  of	  30	  slides	  from	  cell-­‐line	  data	  processed	  at	  the	  M.D.	  Anderson	  Cancer	  Cen-­‐ter.	  
	  
Preparation,	  layout,	  printing	  and	  quantification	  of	  lysate	  array	  sam-­
ples	  Homogenized	  cell	  pellets	  consisting	  of	  cellular	  proteins	  are	  derived	   from	  cells	  grown	  in-­vitro	  or	  from	  tissue	  samples	  in-­vivo.	  Samples	  are	  lysed	  and	  the	  protein	  extract	  obtained	  is	  diluted	  based	  on	  the	  design	  of	  each	  exper-­‐iment.	  In	  the	  slides	  comprising	  the	  data	  sets	  in	  this	  study,	  each	  sample	  un-­‐dergoes	   a	  ½	  serial	  dilution	   four	   times,	   leading	   to	   a	   total	   of	  5	   concentra-­‐tions	   per	   sample.	   These	   initial	   serial	   dilutions	   are	   performed	  manually.	  Diluted	   samples	   are	   then	   robotically	   spotted	   onto	   the	   surface	   of	   slides	  coated	  with	   nitrocellulose.	   In	   our	   experimental	   design,	   each	   sample	   and	  positive	  control	  is	  printed	  in	  five	  dilutions.	  The	  slides	  are	  laid	  out	  as	  grids	  of	   132×44	   spots,	   comprised	   of	   48	   subgrids	   containing	   121	   spots	   each.	  Thus,	  each	  subgrid	  accommodates	  22	  samples	  and	  2	  positive	  control	  sam-­‐ples,	  in	  5	  dilutions	  each.	  A	  subgrid	  is	  also	  printed	  with	  a	  single	  buffer	  spot	  that	  serves	  as	  a	  negative	  or	  background	  control.	   	  Each	  slide	   thus	  accom-­‐modates	   1056	   serially	   diluted	   samples	   and	   96	   positive	   control	   samples	  (with	  5	  dilutions	  per	  sample),	  and	  an	  additional	  48	  negative	  control	  spots	  (Fig.	  2).	  The	  positive	  control	  spots,	  are	  printed	  at	  fixed	  intervals	  across	  the	  length	  and	  breadth	  of	  each	  slide,	  and	  are	  technical	  replicates	  of	  each	  other,	  obtained	  from	  a	  single	  batch	  of	  standard	  mixed	  cell	  lysate	  [133].	  Since	  the	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controls	  are	  designed	  to	  contain	  sufficient	  amount	  of	  each	  of	  the	  proteins	  in	  the	  antibody	  panel	  for	  reliable	  detection,	  similar	  levels	  of	  the	  concerned	  protein	  should	  also	  be	  detected	  in	  experimental	  samples	  when	  the	  appro-­‐priate	  dilution	  of	   antibody	   is	   used.	  The	  negative	   control	   spots	   consist	   of	  buffer	   containing	   no	   protein	   and	   are	   hence	   informative	   of	   the	   level	   of	  background	  signal	  generated.	  	  	  
	  Figure	  2.	  	  In	  the	  experimental	  design	  we	  use	  for	  the	  analysis	  of	  the	  samples	  in	  sets	  A	  and	  B,	   lysate	  is	  spotted	  in	  96	  arrays	  consisting	  of	  22	  samples,	  two	  positive	  controls	  and	  one	  buffer	  spot	  each.	  Each	  of	  the	  samples	  and	  the	  positive	  controls	  is	  printed	  in	  five	  1:2	  serial	  dilutions	  each.	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Protein	  in	  each	  sample	  is	  quantified	  by	  washing	  the	  slide	  with	  a	  solution	  of	  primary	   antibody	   followed	  by	   secondary	   antibody.	   The	  biotinylated	   sec-­‐ondary	  antibody	   interacts	  with	   a	   streptavidin	  bound	  peroxidase	   to	   cata-­‐lyze	   the	   deposition	   of	   a	   biotinylated	   brown	   tyramide	   compound	   on	   the	  surface	  of	   the	   spot.	  The	   intensity	  of	   the	   colored	   signal	   thus	   generated	   is	  proportional	   to	   the	  amount	  of	   secondary	  antibody	  and	  protein	  bound	   to	  the	  slide.	  Signal	  intensities	  obtained	  by	  scanning	  images	  of	  the	  slides	  were	  quantified	  by	  MicroVigene	  software	  [134].	  These	  are	  then	  translated	  into	  relative	   protein	   concentrations	   using	   an	   R	   package	   called	   SuperCurve	  [135].	   SuperCurve	   estimates	   the	   concentrations	   of	   all	   the	   samples	   on	   a	  slide	  with	  respect	  to	  one	  another.	  The	  estimation	  is	  based	  on	  the	  assump-­‐tion	   that	   all	   the	   samples	   on	   a	   slide	   lie	   on	   a	   single	   dose	   response	   curve,	  since	  the	  hybridization	  kinetics	  of	  all	  samples	  have	  similar	  chemistry.	  The	  curve	   thus	  obtained	  may	  be	  used	   to	  obtain	   the	   relative	   concentration	  of	  each	  sample	  on	  the	  slide.	  
	  
Assessment	  of	  data	  quality	  	  The	  effectiveness	  of	  normalization	  was	  assessed	  based	  on	  the	  behavior	  of	  biological	  and	   technical	   replicates	  compared	  before	  and	  after	  normaliza-­‐tion.	  Successful	  normalization	  should	  reduce	  noise,	  resulting	  in	  improved	  comparability	  of	  data	  and	  should	  bring	  replicates	  closer	  to	  each	  other.	  We	  define	  technical	  replicates	  as	  spots	  that	  are	  printed	  from	  lysate	  that	  was	  obtained	  from	  a	  single	  batch	  of	  cells	  in	  a	  single	  experiment.	  When	  printed	  onto	  a	  single	  slide,	  they	  are	  called	  intraslide	  replicates	  and	  when	  printed	  onto	   different	   slides,	   they	   are	   interslide	   replicates.	   For	   example,	   all	   the	  positive	   control	   spots	  belonging	   to	  a	   single	  dilution	  on	  a	   single	   slide	  are	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intraslide	   technical	   replicates	   because	   they	  were	   obtained	   from	   a	   single	  mix	   of	   cells	   and	   subjected	   to	   dilution	   in	   a	   batch	   before	   the	   lysate	   was	  printed	  onto	  slides.	  Biological	  replicates	  are	  spots	  that	  are	  printed	  from	  cell	   lysate	   obtained	   from	   cells	   that	   were	   subjected	   to	   the	   same	   experi-­‐mental	  conditions,	  but	  in	  separate	  batches.	  For	  example,	  in	  procuring	  da-­‐taset	  B,	  SKMEL-­‐133	  cells	  were	  grown	  in	  3	  different	  petri-­‐dishes,	  and	  each	  was	  subjected	  to	  normal	  medium	  spiked	  with	  a	  dose	  of	  EGF	  ligand.	  They	  were	   then	   used	   to	   yield	   three	   separate	   cell	   pellets	   that	  when	   lysed	   and	  printed	  onto	  a	  slide,	  gave	  rise	  to	  biological	  replicate	  spots.	  	  	  We	  expect	  technical	  and	  biological	  replicates	  to	  have	  different	  degrees	  of	  variability.	  Similarity	  of	   technical	  replicates	   is	   indicative	  of	   the	  reliability	  and	   uniformity	   of	   steps	   in	   the	   procedure	   such	   as	   printing,	   probing	   and	  scanning.	  On	  the	  other	  hand,	  biological	  replicates	  may	  vary	  for	  a	  number	  of	   reasons.	   The	   heterogeneity	   inherent	   to	   populations	   of	   cells	   obtained	  from	  both	  cell	  lines	  and	  tumors	  may	  make	  subsets	  of	  such	  populations	  be-­‐have	  differently	  when	  subjected	  to	  the	  same	  treatment.	  Several	  other	  fac-­‐tors	  could	  introduce	  biological	  variation,	  such	  as	  time	  to	  freezing	  and	  the	  presence	  of	  stromal	  and	  endothelial	  cells	  in	  tumor-­‐derived	  samples,	  or	  the	  sample	  preparation	  method	  used	  [136-­‐139].	  Thus	  when	  technical	  variabil-­‐ity	   is	   low,	   the	   differences	   between	   biological	   replicates	   can	   yield	   useful	  information	  about	  cellular	  variability	  in	  the	  samples	  studied.	  	  To	  determine	  how	  spatial	  normalization	  improves	  the	  quality	  of	  RPPA	  da-­‐ta,	  we	  calculated	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1. Agreement	   between	   interslide	   and	   intraslide	   technical	   replicates	   across	  16	  pairs	  of	  duplicate	  slides	  from	  dataset	  A,	  and	  53	  pairs	  of	  duplicate	  slides	  from	  dataset	  B.	  2. Agreement	   between	   intra-­‐slide	   biological	   replicates	   in	   a	   238-­‐slide	  mela-­‐noma	  cell	  line	  study.	  Agreement	  was	  evaluated	  with	  the	  Pearson’s	  correlation	  (ρ)	  between	  cor-­‐responding	  spot	  intensities	  (IA	  and	  IB)	  across	  duplicate	  slides	  and	  the	  coef-­‐ficient	   of	   variation	   (%CV)	   between	   replicates	   within-­‐slide,	   where	   µ	   de-­‐notes	  the	  mean	  and	  σ	  the	  standard	  deviation	  of	  the	  spot	  intensities	  (I)	  or	  protein	  concentrations	  (P)	  measured.	  	  	  




E[(IA − µIA )(IB − µIB )
σ IAσ IB
…………	  	  (1)	  	  	  
%CV = σ P ×100
µP
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  (2)	  
	  	  	  
Results	  
Bilinear	   interpolation	  of	  correction	  factors	  to	  remove	  spatial	  biases	  
in	  RPPA	  data	  The	  central	  assumption	  is	  that	  in	  the	  absence	  of	  spatial	  variance	  all	  posi-­‐tive	  controls	  of	  a	  given	  dilution	  should	  yield	  equal	  intensities.	  Consequent-­‐ly,	   observed	   variability	   of	   positive	   control	   intensities	   is	   a	   survey	   of	   the	  spatial	  bias	  on	  the	  slide.	  	  With	  this	  information,	  we	  can	  systematically	  fac-­‐tor	  out	  the	  spatial	  bias	  at	  any	  location	  based	  on	  neighboring	  positive	  con-­‐trol	  intensities.	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We	  define	  the	  relationship	  between	  the	  measured	  sample	  intensity	  I(x,y)	  and	   the	   true	   intensity	   I’(x,y)	   in	   terms	   of	   a	   correction	   factor	   CF(x,y)	   that	  represents	  spatial	  variance.	  	  
I '(x, y) = I(x, y)CF(x, y) 	  	  Correction	   factors	   are	   simply	   the	   ratio	   of	   positive	   control	   intensities	  PCI(x,y)	  to	  some	  reference	  intensity	  <PCI>.	  	  	  
CF(x, y) = PCI(x, y)PCI 	  	  Here,	  we	  choose	  the	  mean	  positive	  control	  intensity	  <PCI>	  to	  be	  the	  refer-­‐ence	  intensity.	  CF	  values	  above	  1	  indicate	  regions	  on	  the	  slide	  where	  there	  is	  a	  bias	  towards	  larger	  intensities.	  	  CF	  values	  below	  1	  indicate	  regions	  on	  the	  slide	  where	  there	  is	  a	  spatial	  bias	  towards	  smaller	  intensities.	  	  However,	  these	  correction	  factors	  are	  not	  directly	  calculable	  at	  sample	  lo-­‐cations	  precisely	  because	  those	  locations	  do	  not	  contain	  positive	  controls.	  	  To	   compensate	   for	   this	  missing	   information,	  we	  use	   interpolation	   to	   ap-­‐proximate	  pseudo-­‐positive	  control	  intensities	  at	  the	  sample	  locations.	  	  Interpolation	   is	   the	   calculation	   to	   approximate	   the	   value	   of	   a	   function	  f(x,y)	   at	   specific	   locations	   (x,y)	   given	   fixed	   knots	   or	   measured	   function	  values	  at	  neighboring	  locations	  f(xc,	  yc)	  and	  is	  analogous	  to	  “Connect	  the	  Dots”.	   Linear	   interpolation	   means	   we	   connect	   the	   dots	   with	   lines.	   	   The	  points	  lying	  on	  the	  lines	  between	  the	  dots	  are	  the	  interpolated	  values,	  and	  the	   dots	   themselves	   are	   fixed	   knots	   or	   anchor	   points.	   The	   interpolated	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values	  are	  approximations	  inferred	  based	  on	  nearest	  neighbor	  data.	  In	  this	  case,	  we	  will	  use	   the	  measured	  positive	  control	   intensities	   to	   interpolate	  or	  approximate	  pseudo-­‐positive	  control	   intensities	  at	  all	   locations	  on	  the	  slide.	  	  Consider	  a	  location	  (x,y)	  that	  lies	  between	  four	  measured	  positive	  control	  spots	   with	   corresponding	   intensities	   PCI(xa,ya),	   PCI(xa,yb),	   PCI(xb,ya),	  
PC(xb,yb).	  
PCI *(x, ya ) =
xb − x
xb − xa
PCI(xa , ya )+
x − xa
xb − xa
PCI(xb , ya ) 	  
PCI *(x, yb ) =
xb − x
xb − xa
PCI(xa , yb )+
x − xa
xb − xa
PCI(xb , yb ) 	  
PCI *(x, y) = yb − yyb − ya
PCI *(x, ya )+
y − ya
yb − ya
PCI *(x, yb ) 	  These	  are	  pseudo-­‐positive	  control	  intensities	  (indicated	  by	  an	  asterisk)	  in	  that	  they	  are	  approximations	  for	  what	  a	  control	  intensity	  at	  that	  location	  would	  have	  been	  had	  it	  been	  spotted	  with	  control	  sample.	  The	  correction	  factors	  at	  these	  locations	  are	  calculable	  with	  simple	  division	  by	  the	  refer-­‐ence	  positive	  control	  intensity.	  	  
CF*(x, y) = PCI(x, y)PCI 	  	  	  The	   bilinear	   interpolation	   calculation	   described	   above	   reflects	   only	   our	  assumptions	  about	  the	  smoothness	  of	  the	  spatial	  bias	  between	  measured	  positive	  control	  locations.	  	  It	  says	  nothing	  about	  the	  relationship	  any	  sam-­‐ple	  intensity	  has	  to	  another	  sample	  intensity.	  A	  similar	  correction	  can	  be	  applied	  after	  performing	  a	  cubic	  spline	  interpolation	  between	  the	  correc-­‐tion	   factors.	   Overall,	   the	   results	   of	   normalization	   using	   spline	   interpola-­‐tion	  are	  similar	  to	  those	  with	  bilinear	  interpolation	  (supplementary	  table	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S3).	  Hence	  we	  use	  the	  simpler	  of	   the	  two,	  bilinear	   interpolation,	   for	  nor-­‐malization	  (supplementary	  Figure	  S1).	  Further,	  in	  the	  sample	  and	  control	  format	   used	   in	   our	   experiments,	   there	   are	   96	   sets	   of	   positive	   controls	  printed	  in	  5	  dilutions	  each.	  We	  use	  the	  median	  of	  each	  set	  as	  anchors	  for	  our	  interpolation	  step	  as	  this	  dilution	  is	  the	  most	  likely	  to	  be	  in	  the	  linear	  range	  of	  the	  assay	  for	  the	  set	  of	  antibodies	  used	  in	  the	  experiment.	  Users	  of	  the	  method	  are	  encouraged	  to	  design	  their	  experiments	  such	  that	  all	  the	  query	  samples	  are	  contained	  within	   the	   interpolation	  region	  of	   the	  posi-­‐tive	  controls.	   In	  our	  design,	  a	  portion	  of	   the	  slide	  (1/12th)	  does	  not	  have	  positive	   controls	   at	   its	   periphery	   and	   hence,	   each	   sample	   in	   this	   region	  was	  normalized	  by	  the	  closest	  correction	  factor	  evaluated.	  	  	  	  
Spatial	  normalization	  improves	  Coefficient	  of	  Variation	  between	  bio-­
logical	  replicates.	  	  Spatial	   normalization	   improves	   agreement	   between	   intraslide	   biological	  replicates	   in	  dataset	  B	  and	   ‘rescues’	  previously	  discarded	  slides	  enabling	  further	   analysis	   of	   these	   proteins.	   Melanoma	   cell	   line	   samples	   were	   ac-­‐quired	  for	  a	  large	  study	  aimed	  at	  understanding	  the	  basis	  of	  RAF	  inhibitor	  resistance	  in	  certain	  melanoma	  cell	  lines.	  Cell	  lysate	  was	  obtained	  from	  a	  melanoma	   cell	   line	   SKMEL-­‐133	  and	   subjected	   to	   various	  drug	   treatment	  conditions	  in	  triplicate,	  resulting	  in	  approximately	  300	  samples	  that	  were	  then	  quantified	  using	  RPPA.	  Agreement	  between	  the	  biological	  replicates	  was	  calculated	  before	  and	  after	  normalization.	  Around	  10%	  of	   the	  slides	  (25/238)	  show	  increases	  of	  over	  5%	  in	  agreement	  between	  biological	  rep-­‐licates	   after	   normalization	   whereas	   only	   1.2%	   (3/238)	   slides	   show	   a	  worsening	   of	   CV	   by	   over	   5%	   with	   normalization.	   Despite	   increased	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agreement	   overall,	   biological	   replicates	   show	   different	   degrees	   of	   im-­‐provement	  with	  spatial	  normalization	  (Fig.	  3)	  	  
	  Figure	  3.	  Coefficient	  of	  variation	  (%CV)	  of	  biological	  replicates	  across	  all	  antibodies	  be-­‐fore	   and	   after	   normalization	   clearly	   improve	   with	   normalization.	   The	   degree	   of	   im-­‐provement	   varies	   from	   antibody	   to	   antibody	   (higher	   for	   EGFR-­‐pY992	   and	   cJUN-­‐pS73	  than	  YB1-­‐pS102)	  and	  is	  significant	  for	  many	  antibodies	  relevant	  to	  signaling	  in	  the	  mela-­‐noma	  cell	  lines	  studied.	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The	  data	  from	  this	  study	  were	  used	  to	  train	  a	  mathematical	  model	  of	  mel-­‐anoma	   biology	   in	   SKMEL-­‐133.	   To	   maximize	   model	   accuracy,	   only	   data	  points	   with	   sufficient	   reliability	   were	   kept	   for	  model	   incorporation	   and	  training.	  Slides	  were	  selected	  if	  the	  average	  coefficient	  of	  variation	  (%CV)	  of	  biological	  replicates	  within	  each	  slide	  was	  seen	  to	  be	  less	  than	  or	  equal	  to	  15%.	  This	  threshold	  was	  arbitrarily	  selected	  by	  the	  authors	  and	  is	   left	  to	  the	  discretion	  of	  the	  user.	  %CV,	  which	  is	  the	  ratio	  of	  the	  standard	  devia	  
Figure	  4.	  Spatial	  normalization	  reduces	  variance	  between	  biological	  replicates	  in	  the	  ma-­‐jority	  of	  the	  slides	  comprising	  a	  melanoma	  cell	  line	  study.	  In	  the	  study,	  a	  cutoff	  coefficient	  of	  variation	  (CV)	  of	  15%	  is	  used	  to	  decide	  whether	  slides	  are	  retained	  for	  biological	  anal-­‐ysis.	   After	   spatial	   normalization,	   CVs	   in	   8	   slides	   (Caspase	   9,	   IGFBP2,	   ATR,	   COX2,	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FAK_pY397,	  BCL2(mouse),	  PARP,	  AKT)	  that	  were	  previously	  unusable	  drop	  to	  acceptable	  values.	  One	  slide	  -­‐	  PCNA(mouse)	  -­‐	  that	  had	  earlier	  been	  used	  in	  analysis	  is	  rejected	  after	  normalization.	  	  	  tion	  between	  observations	   to	   the	  mean	  of	   those	  observations,	   expressed	  as	  a	  percentage,	  is	  a	  good	  measure	  of	  signal	  to	  noise	  in	  biological	  data	  and	  rises	  with	  noise	  in	  the	  data.	  A	  set	  of	  168	  slides	  was	  originally	  selected	  after	  discarding	  saturated	  and	  defective	  slides.	  Of	  the	  168,	  when	  we	  evaluated	  %CV	  across	  all	  biological	  replicates	  in	  each	  slide,	  15	  slides	  were	  unusable	  because	  of	  %CV	  greater	  than	  15%.	  After	  normalization,	  only	  7	  slides	  had	  %CV	  greater	  than	  15%.	  The	  slides	  that	  were	  rescued	  by	  spatial	  normaliza-­‐tion	  measured	  AKT,	  PARP,	  BCL2,	  BIM,	  ATR,	  YAP,	  IGFBP	  and	  FAK	  (Fig.	  4).	  In	   certain	   cases,	  %CV	  appears	   to	   rise	   after	  normalization.	  This	   could	   re-­‐flect	  real	  noise	  present	  in	  the	  data.	  However,	  the	  cases	  where	  this	  occurs	  	  are	   those	  where	  %CV	   is	   significantly	  below	  the	  cutoff	  of	  15%	  and	  hence	  this	  did	  not	  affect	  the	  selection	  of	  antibodies	  in	  our	  study.	  To	  further	  verify	  this	  result,	  we	  also	  calculated	  the	  Z’-­‐factor	  [140]	  of	  each	  slide	  before	  and	  after	  spatial	  normalization.	  In	  agreement	  with	  the	  %CV	  improvements	  we	  observed	   in	   biological	   replicates,	   the	   per-­‐slide	   Z’-­‐factor	   evaluated	   in	   da-­‐taset	  B	  also	   improves	   in	  >	  98%	  of	  the	  slides	  used	  in	  the	  experiment	  (de-­‐tails	  and	  calculations	  provided	  in	  supplementary	  materials,	  including	  Fig.	  S3).	  	  	  
Spatial	  normalization	  modestly	  improves	  the	  agreement	  between	  in-­
ter-­slide	  replicates	  	  To	  evaluate	  whether	  spatial	  normalization	   improved	  data	  quality	  signifi-­‐cantly,	  we	  compared	  the	  agreement	  between	  technical	  and	  biological	  rep-­‐
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licates	  before	  and	  after	  normalization.	  We	  compared	  the	  Pearson’s	  corre-­‐lation	   of	   the	   estimated	   concentrations	   of	   samples	   printed	   at	   equivalent	  locations	  across	  69	  pairs	  of	  duplicate	  slides	  procured	  independently	  from	  sets	  A	  and	  B	  to	  assess	  interslide	  reproducibility.	  Here,	  duplicate	  slides	  are	  slides	  that	  were	  printed	  with	  the	  same	  samples	  in	  equivalent	  locations	  on	  each	  slide.	  	  	  	  Many	   slide	  pairs	   improve	   in	   overall	   correlation	  between	   concentrations,	  with	  only	  a	  minority	  of	  the	  slide	  pairs	  showing	  a	  large	  such	  improvement.	  Further,	   slides	   showing	   a	   modest	   improvement	   in	   the	   behavior	   of	   in-­‐terslide	   technical	   replicates	   with	   normalization	   often	   show	   greater	   im-­‐provements	  in	  concordance	  of	  biological	  replicates	  (Fig.	  5	  and	  supplemen-­‐tary	   table	   S4).	   Earlier	   studies	   using	   RPPA	   have	   consistently	   shown	   that	  such	  correlations	  evaluated	  between	  the	  concentrations	  of	  interslide	  rep-­‐licates	   are	   generally	   high	   [133]	   but	  may	  not	   be	   the	  best	  measure	   of	   im-­‐provement	  in	  data	  quality	  after	  normalization.	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  Figure	  5.	  Correlation	  between	  concentrations	  of	  samples	  printed	  across	  duplicate	  slides	  increases	   slightly	   with	   normalization	   (upper	   panels,	   L!R,	   melanoma	   samples	   and	  probed	  with	  anti-­‐pMAPK	  antibody).	  Coefficient	  of	  variation	  between	  the	  concentrations	  of	  biological	  replicates	  printed	  on	  one	  of	  these	  slides	  improves	  after	  normalization	  (low-­‐er	  panels,	  L!R).	  	  
Spatial	   normalization	   improves	   Intra-­slide	   reproducibility	   of	   tech-­
nical	  replicates	  The	  slides	  evaluated	  for	  interslide	  reproducibility	  each	  have	  480	  positive	  controls,	  spotted	  as	  96	  sets	  of	  5	  dilutions	  each.	  The	  96	  points	  within	  a	  dilu-­‐
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tion	  are	  hence	  all	  technical	  replicates	  of	  one	  another.	  While	  the	  normaliza-­‐tion	  method	  uses	  one	  of	   these	   sets,	   the	  median	   set,	   as	   anchor	  points	   for	  evaluating	  spatial	  variation	  and	  correction	  factors,	  we	  can	  use	  the	  remain-­‐ing	   dilutions	   of	   the	   positive	   controls	   to	  measure	  %CV	   between	   each	   set	  before	   and	   after	   normalization.	   Doing	   this	   showed	   significant	   improve-­‐ments	  in	  agreement	  between	  each	  such	  set	  of	  technical	  replicates,	  across	  most	   antibodies	   used.	   (Fig.	   6)	   In	   the	  melanoma	   data-­‐set,	   agreement	   be-­‐tween	   technical	   replicates	   showed	  an	   average	   improvement	  of	  4%,	  with	  %CV	   falling	   from	   12%	   to	   8%,	   after	   normalization	   across	   slides	   probed	  with	  different	  antibodies.	   	   Further,	  16	  out	  of	   the	  168	  antibodies	   showed	  improvements	   of	   10%	   or	   above	   in	   the	   coefficient	   of	   variation	   between	  technical	  replicates.	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  Figure	  6.	  Coefficient	  of	  variation	  between	  intensities	  of	   intraslide	  technical	  replicates	   in	  dataset	   B	   decreases	   significantly	  with	   normalization.	   One	   out	   of	   5	   dilutions	   of	   positive	  controls	  is	  used	  for	  spatial	  normalization.	  The	  correlation	  of	  the	  remaining	  positive	  con-­‐trols,	  which	  are	  technical	  replicates	  within	  each	  dilution,	  is	  observed	  after	  normalization.	  Correlations	  increase	  with	  normalization	  for	  each	  of	  the	  observed	  dilutions.	  	  
Discussion	  RPPA	  is	  one	  of	  two	  main	  techniques	  used	  in	  large-­‐scale	  proteomics	  studies	  today	  –	  array	  based	  techniques	  and	  mass	  spectrometry.	  High-­‐throughput,	  low	  sample	  requirement	  and	  high	  sensitivity	  make	  it	  a	  promising	  technol-­‐
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ogy	  with	  which	   to	   examine	  protein	  networks	   in	   a	   variety	   of	   systems	   in-­‐cluding	  cell	   lines	  and	  tissue	  samples.	  However,	  some	  of	   the	   features	   that	  make	  RPPA	  an	  appropriate	  choice	  for	  several	  kinds	  of	  proteomics	  studies,	  such	   as	   antibody-­‐based	   detection,	   where	   antibodies	   have	   may	   different	  target-­‐affinities	  and	  variable	  specificities,	  also	  add	  noise	  to	  the	  data	  it	  gen-­‐erates.	  Hence	  noise	  reduction	  and	  data	  normalization	  are	  essential	  for	  the	  successful	   application	   of	   RPPA.	   	   Our	   normalization	   technique	   evaluates	  one	  source	  of	  noise	  in	  RPPA	  data	  –	  spatial	  variation	  –	  and	  uses	  the	  meas-­‐ured	  variation	  to	  correct	  the	  data	  leading	  to	  increased	  reproducibility	  be-­‐tween	  duplicates	  in	  various	  studies.	  The	  method	  also	  makes	  the	  data	  from	  previously	  discarded,	  noisy	  slides	  usable	  in	  analysis,	  potentially	  expanding	  the	  scope	  of	  the	  biological	  questions	  that	  a	  set	  of	  RPPA	  experiments	  may	  address.	  	  	  Among	   the	   genomics	  platforms,	   such	   as	  DNA	  microarrays,	   standards	   for	  experimental	   design	   and	   analysis	   have	   greatly	   improved	   the	   quality	   of	  those	  data	  and	   the	   scope	  of	   the	   studies	   that	   they	  enable	   [141-­‐144].	  This	  has	   lead	   to	  collaborative	  efforts	  such	  as	   the	  TCGA	  that	  have	  significantly	  enhanced	   our	   understanding	   of	   various	   cancers	   [1].	   Among	   the	   protein	  activity	  measurement	   platforms,	   there	   are	   fewer	  methods	   that	   similarly	  address	  data	  quality.	  One	  such	  method	  [145],	  in	  which	  control	  samples	  are	  used	  to	  normalize	  for	  spatial	  and	  scaling	  errors	  in	  RPPA	  data	  successfully	  reduces	   intra-­‐array	   replicate	  CV	  by	  up	   to	  70%.	  However	   these	   improve-­‐ments	  were	  the	  result	  of	  printing	  of	  as	  many	  control	  samples	  as	  each	  slide	  contained	  query	   samples	   and	   is	   hence	   expensive.	   Further,	   the	  published	  method	  was	  only	  applicable	  to	  a	  specified	  sample	  layout.	  Our	  method	  cor-­‐
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rects	  a	   significant	  and	  systematic	   source	  of	  bias	   in	  RPPA	  data	  effectively	  reducing	   error	   in	   sample	   sets	   normalized	   with	   relatively	   few	   controls.	  Among	   the	  melanoma	  data	  we	  corrected,	   for	   instance,	   fewer	   than	  2%	  of	  the	  samples	  were	  used	  to	  normalize	  a	  total	  of	  5808	  samples.	  Further,	  the	  method	  is	  flexible,	  allowing	  the	  user	  to	  correct	  for	  spatial	  biases	  in	  a	  varie-­‐ty	  of	   formats	   containing	   identical	   control	   samples	   that	   contain	  a	   level	  of	  the	  protein	  of	  interest	  that	  is	  within	  the	  linear	  detection	  range	  of	  the	  assay	  used.	  Others	  in	  the	  research	  community	  have	  similar	  goals	  and	  improved	  standardization	  of	  analysis	  methods	  will	  help	  realize	  the	  potential	  of	  RPPA	  in,	  e.g.,	  characterizing	  the	  signaling	  response	  to	  drug	  treatment	  or	  in	  train-­‐ing	  mathematical	  models	  of	  biological	  systems.	  	  	  As	  this	  manuscript	  was	  completed,	  two	  other	  alternative	  methods	  for	  spa-­‐tial	   normalization	  of	  RPPA	  data	  were	  published	   [146,	   147].	  The	   first,	   by	  Troncale	  et	  al.,	  uses	  a	  non-­‐parametric	  model	  that	  takes	  into	  account	  every	  sample’s	  Row	  and	  Column	  location	  while	  fitting	  the	  obtained	  intensities	  to	  relative	  protein	  expressions,	   thus	  adjusting	   for	   spatial	   effects	   along	  with	  other	   sources	   of	   variation	   addressed	   by	   the	   paper,	   such	   as	   background	  and	   total	   protein	   deposited	   at	   each	   spot.	   The	  method	   of	   Neeley	   et	   al.	   is	  similar	  in	  ideology	  to	  ours,	  in	  that	  it	  uses	  the	  variation	  observed	  between	  identical	  controls	  printed	  at	  various	  locations	  on	  each	  array	  to	  normalize	  for	  spatial	  effects.	  The	  correction	  is	  model	  based,	  and	  is	  specific	  to	  an	  ar-­‐ray	  format	  that	  is	  commonly	  used	  in	  the	  community.	   	  While	  a	  systematic	  comparison	   of	   existing	  methods	  would	   help	   a	   user	   to	   select	   the	  method	  best	  suited	  to	   their	  experiment	  and	  data,	   this	   is	  beyond	  the	  scope	  of	  our	  current	  work.	  We	  compare	  the	  changes	  in	  reproducibility	  of	  data	  observed	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using	  our	  method	  with	  Neeley	  et	  al	  across	  the	  antibodies	  in	  the	  melanoma	  dataset.	  These	  results	  are	  provided	  in	  the	  supplementary	  materials	  (sup-­‐plementary	  Figure	  S2).	  More	  extensive	  comparisons	  of	  the	  existing	  meth-­‐ods	  may	  aid	  in	  the	  selection	  of	  a	  set	  of	  standard	  methods	  for	  data	  normali-­‐zation,	  or	  an	  improved	  understanding	  of	  what	  quantification	  and	  normali-­‐zation	   methods	   work	   the	   best	   for	   different	   types	   of	   experiments.	   This	  would	  be	  beneficial	  to	  the	  RPPA	  community,	  where	  comparisons	  of	  exper-­‐imental	  results	  are	  currently	  confounded	  by	  a	  lack	  of	  standardization.	  	  A	  metric	   frequently	  used	  to	  assess	  data	  quality	   in	  RPPA	   is	   interslide	  and	  intraslide	  correlation	  between	  spot	  intensities	  of	  technical	  replicate	  spots	  [133].	  While	  this	  gives	  us	  some	  confidence	  about	  the	  reliability	  of	  the	  re-­‐sults,	   it	  may	  not	   be	   an	   adequate	  measure	  of	   reproducibility.	   Since	  RPPA	  has	  a	  low	  dynamic	  range	  as	  compared	  to	  some	  other	  proteomics	  methods,	  this	  range	  is	  often	  expanded	  by	  printing	  multiple	  dilutions	  of	  each	  sample	  on	   the	  surface	  of	  a	  single	  slide.	  The	  dilutions	  of	  a	  sample	  may	  be	  widely	  separated	  in	   intensity,	  and	  correlations	  measured	  across	  all	  spot	   intensi-­‐ties	  on	  a	  slide	  may	  be	  biased	  by	  the	  range	  of	  intensities	  spanned	  by	  each	  slide	   (Fig.	   7).	  When	   evaluating	   interslide	   correlations,	  we	   attempt	   to	   re-­‐duce	   this	   bias	   by	   comparing	   relative	   protein	   concentrations	   rather	   than	  intensities.	   Nonetheless,	   measures	   of	   intraslide	   technical	   and	   biological	  replicate	  equality	  can	  be	  more	  informative	  of	  data	  quality	  than	  Pearson’s	  correlation.	  Other	  metrics	  of	  data	  quality,	  such	  as	  the	  Z’factor	  [140]	  and	  a	  Welch’s	  t-­‐statistic	  [148]	  to	  evaluate	  the	  mean	  difference	  between	  the	  posi-­‐tive	  and	  negative	  controls	  before	  and	  after	  normalization	  also	  showed	  im-­‐
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provements	   from	   normalization	   for	   the	   vast	   majority	   of	   samples.	  	  (supplementary	  figures	  S3	  and	  S4).	  	  	  
	  Figure	   7.	   Correlation	   calculations	   performed	   using	   intensities	   of	   all	   spots	   printed	   onto	  duplicate	  slides	  may	  be	  a	  misleading	  measure	  of	  reproducibility	  because	  of	  experimental	  design	  that	  uses	  multiple	  dilutions	  to	  evaluate	  sample	  concentrations.	  In	  the	  case	  of	  two	  identical	   slides	   probed	  with	   anti-­‐pBAD	   antibody,	   overall	   correlation	   coefficient	   R=0.82	  whereas	  correlations	  of	  the	  individual	  dilutions	  are	  lower.	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  The	  spatial	  normalization	  technique	  we	  implemented	  not	  only	  significant-­‐ly	  decreased	  coefficient	  of	  variation	  improved	  agreement	  between	  biolog-­‐ical	  and	  technical	  replicates	  within	  slides,	  but	  also	  made	  it	  possible	  to	  ana-­‐lyze	  the	  data	  from	  many	  slides	  that	  were	  previously	  unusable	  because	  of	  high	  variation.	  A	  particular	  example	  is	  our	  use	  of	  the	  antibody	  for	  PARP-­‐1	  in	   a	   study	   of	   melanoma	   samples	   subjected	   to	   various	   treatment	   condi-­‐tions,	  where	  the	  %CV	  between	  biological	  replicates	  decreased	   from	  21%	  to	  13%,	  enabling	  more	  reliable	  use	  in	  the	  study	  after	  normalization.	  Poly	  (ADP	   ribose)	   polymerase	   (PARP)	   proteins	   (PARP-­‐1	   and	   PARP-­‐2)	   play	   a	  critical	   role	   in	   controlling	  necrosis	   and	   apoptotic	   cell	   death.	  These	  PARP	  proteins	  are	  located	  inside	  the	  nucleus	  and	  take	  part	  in	  DNA-­‐repair	  in	  re-­‐sponse	   to	   DNA	   breaks	   and	   facilitate	   transcription,	   replication	   and	   DNA	  base	  excision	  repair	  [149].	  PARP	  inhibitors	  (Olaporib,	  iniparib	  and	  velipa-­‐rib)	   are	   undergoing	   clinical	   trials	   in	   BRCA	   mutated	   ovarian	   and	   breast	  cancer	   patients	   [150].	  Furthermore,	   PARP-­‐1	  has	   been	   linked	   to	   altered	  control	   of	   p53-­‐mediated	   DNA	   response	   and	   NFKappa-­‐B	   response	  [151].	  Consequently,	   accurate	   quantification	   of	   cleaved	   PARP-­‐1	   could	   be	  critical	   in	   understanding	   the	   complex	   signaling	   mechanisms	   involving	  PARP-­‐inhibition	  as	  well	  as	  perturbations	  involving	  BRCA1	  and	  BRCA2.	  	  	  	  Other	   proteins	   similarly	   rescued	   in	   this	   and	   other	   studies	   could	   expand	  the	   scope	  of	   the	  biological	   problems	  addressed	  by	  RPPA.	  One	   context	   in	  which	   spatial	   normalization	   could	   be	   very	   relevant	   is	   in	   the	   analysis	   of	  tumor	  samples	  using	  RPPA,	  that	  due	  to	  requirements	  of	  throughput,	  cost	  and	  limited	  availability	  of	  patient	  material,	  are	  often	  unable	  to	  have	  sam-­‐
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ple	  replicates	  within	  slides.	  One	  such	  effort,	  belonging	  to	  the	  umbrella	  of	  TCGA	   projects,	   measures	   and	   compares	   protein	   abundance	   data	   across	  various	   tumors.	   In	  cases	  such	  as	   this,	   spatial	  variation	  alone	  could	  cause	  the	   appearance	  of	   differences	   that	  may	  bias	   the	   results.	  Hence	   it	   is	   very	  important	   that	   these	   data	   be	   appropriately	   normalized	   before	   use	   and	  analysis	  in	  other	  projects	  R	  code	  for	  our	  spatial	  normalization	  method	  can	  be	  used	  in	  conjunction	  with	  MicroVigene	  and	  SuperCurve.	  It	  is	  flexible	  and	  may	  be	   adapted	   to	   several	   different	   kinds	   of	   experimental	   designs,	  with	  the	   user	   specifying	   the	   locations	   of	   positive	   controls	   or	   other	   identical	  samples	  to	  be	  used	  as	  reference	  points	  for	  normalization.	  	  	  Our	   method	   is	   one	   of	   several	   early	   efforts	   for	   the	   standardization	   and	  quality	   control	   of	   RPPA	   data.	   As	   data	   acquisition	  methods	   improve	   and	  RPPA	   moves	   into	   more	   widespread	   use,	   we	   advocate	   the	   adoption	   of	  common	   standards	   for	   the	   evaluation	   and	   correction,	  where	  possible,	   of	  systematic	  errors	  in	  RPPA	  data	  as	  well	  as	  in	  the	  analysis	  of	  these	  data	  to	  enable	   larger,	  multi-­‐center	   studies	  and	   improve	  comparability	  across	   in-­‐dividual	  studies.	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